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1 
Abstract 
Increased activation of the complement system has been measured in various malignancies. 
Previous studies indicated that the complement system activates endothelial cells (ECs) and 
neutrophils. However, in the context of tumor progression, knowledge on the crosstalk 
between the vascular endothelium, the complement system and the neutrophil associated 
innate immunity is still scarce. Here, we report the tumor-specific complement activation in 
patients suffering from malignant melanoma. Using mouse and human tumor tissue samples, 
we showed that accumulation of complement effectors such as C3 fragments and C5a around 
tumor blood vessel walls were increased. Moreover, we detected high levels of the mannose 
binding lectin (MBL) at the endothelium suggesting the involvement of the lectin pathway as 
main trigger of the melanoma mediated complement activation. However, the complement 
cascade terminated by the formation of the membrane attack complex (MAC) not on the 
endothelium but on perivascular neutrophils. In vitro experiments with human ECs and 
neutrophils confirmed this complement mediated crosstalk. Further in vitro experiments 
demonstrated that MAC positive neutrophils released reactive oxygen species (ROS) and 
neutrophil extracellular traps (NETs). In close proximity to the endothelium, complement 
activated neutrophils were able to increase the vascular permeability allowing the 
transmigration of melanoma cells. MAC deposition on tumor-associated neutrophils was also 
found in human melanomas but not in rarely metastasizing basal cell carcinomas, 
keratoacanthoma, or non-metastatic nevocytic nevi. Interference with the deposition of 
complement factors on the EC surface through the low-molecular weight heparin tinzaparin 
prevented MAC formation and thus ROS and NETs release from neutrophils. Moreover, 
tinzaparin treatment stabilized the vascular permeability and might contribute to a reduced 
metastasis as previously published. In summary, we discovered a triangular communication 
between the complement system, neutrophils and the vascular endothelium mediating 
NETosis, endothelial dysfunction and subsequently melanoma cells extravasation. Therefore, 
targeting complement activation envisions a new therapeutic strategy for the treatment of 
malignant melanoma. 
 
 
 
2 
Zusammenfassung 
Eine verstärkte Aktivierung des Komplementsystems konnte bereits in verschiedenen 
Tumorerkrankungen nachgewiesen werden. Vorangegangene wissenschaftliche Arbeiten 
weisen darauf hin, dass das Komplementsystem Endothelzellen (EZ) und neutrophile 
Granulozyten aktiviert. Dennoch ist das Wissen hinsichtlich der Interaktion zwischen dem 
Gefäßendothel, dem Komplementsystem und dem mit den Neutrophilen assoziierten 
Immunsystem, im Kontext der Tumorprogression, begrenzt. Hier berichten wir über die 
tumorspezifische Komplementaktivierung bei am malignen Melanom erkrankten Patienten. 
In von der Maus stammenden und humanen Gewebeproben haben wir eine vermehrte 
Anreicherung der Komplementeffektoren C3b und C5a um Tumorblutgefäßwände gefunden. 
Darüber hinaus haben wir hohe Spiegel des Mannose bindenden Lektins (MBL) am Endothel 
festgestellt, welche auf eine Beteiligung des Lektin Weges, bei der Melanom vermittelten 
Komplementaktivierung hinweist. Jedoch endete die Komplementkaskade in der Formation 
des Membran Angriff Komplexes (MAK) nicht auf dem Endothel, sondern auf den 
perivaskulären Neutrophilen. In in vitro Experimenten mit humanen EZ und Neutrophilen 
wurde ihre Komplement vermittelte Wechselwirkung bestätigt. In vitro Experimente haben 
auch gezeigt, dass Neutrophile reaktive Sauerstoffspezies (ROS) und neutrophile 
extrazelluläre Fallen (NEF) ausschütten. Komplementaktivierte neutrophile Granulozyten 
waren daher in der Lage, im eng benachbarten Endothel die vaskuläre Permeabilität zu 
erhöhen. Ein Mechanismus, der die Transmigration von Melanomzellen erleichtert. Die 
Ablagerung des MAK auf Tumor assoziierten Neutrophilen wurde in humanem Melanom 
gefunden, aber nicht im selten metastasierenden Basalzellkarzinom, Keratoakanthom, oder 
nicht metastasierenden nävozytischen Nävi. Das niedermolekulare Heparin Tinzaparin 
interferiert mit der Ablagerung der Komplementfaktoren auf der EZ Oberfläche und 
verhindert die MAK Bildung und somit in der Folge die Freisetzung von ROS und NEF aus 
Neutrophilen. Darüber hinaus stabilisierte Tinzaparin die vaskuläre Integrität und reduzierte 
die Metastasierung des Melanoms. Zusammenfassend beschreiben wir hier die trianguläre 
Kommunikation zwischen dem Komplementsystem, neutrophilen Granulozyten und dem 
vaskulären Endothel im Mikromilieu des Melanoms. Aufgrund der hier aufgezeigten 
Bedeutung der Komplement vermittelten NEF-Bildung und der damit einhergehenden 
endothelialen Dysfunktion und Extravasation von Melanomzellen,  erscheint die Inhibition 
der Komplementaktivierung als eine neue therapeutische Strategien bei der Behandlung des 
malignen Melanoms besonders sinnvoll. 
3 
1 Introduction 
1.1 The complement system 
Complement system is a major part of innate immunity and has been traditionally considered 
as the first line of defense against microbial infections. Complement activation can be 
initiated by three distinct pathways: the classical, lectin and alternative pathways (Figure 1)
1
. 
IgM or IgG binds to the surface of microbial intruders to create immune complexes, which 
are recognized by C1q. C1q serves as the initiator of classical pathway activation and it 
subsequently activates C1r and C1s serine protease subunits, which cleave complement 
components C4 and C2, resulting in the formation of C4bC2a, the C3 convertase in the 
classical pathway. 
The activation of lectin pathway can be triggered by the aberrant carbohydrates or 
glycoproteins exposed on the surface of pathogens or damaged cells
2
. The pattern-recognition 
molecules of the lectin pathway are mannose-binding lectin (MBL), ficolins and collectins
1
. 
Collectins have carbohydrate recognition domains, which are able to bind sugar patterns. 
MBL belongs to the collectin family and it can recognize microbial polysaccharides or 
glycoconjugates rich in mannose or N-acetylglucosamine
2
. Similarly, Ficolins contain the C-
terminal recognition fibrinogen-like domains and can recognize acetyl groups on the surface 
of bacteria. After binding, these pattern-recognition molecules will form a complex with 
MBL-associated serine proteases (MASP1 and MASP2), cleaving C4 and C2 to form the C3 
convertase C4bC2a, which is same with classical pathway route. 
The alternative pathway initiates by spontaneous hydrolysis of C3 to form C3(H2O); a 
process also known as the “tickover” of C3
1
. C3(H2O) binds to factor B, and then factor B 
can be cleaved by factor D and results in the formation of the C3 convertase C3(H2O)Bb, 
which is the initial C3 convertase of the alternative pathway. This proteolytic complex can 
convert C3 into reactive C3b. C3b can bind Factor B and Factor D forming the predominant 
alternative pathway C3 convertase C3Bb. Although this convertase is a short lived complex, 
its association with properdin (also known as factor P) can enhance C3Bb stability. 
All of the complement activation pathways lead to the cleavage of C3 into C3a and C3b. C3b 
binds either to the invading pathogen, abnormal cells or to the C3 convertases to generate C5 
convertases. The C5 convertase cleaves C5 into C5a and C5b. In the classical and lectin 
pathways the C5 convertase is composed of C3bC4bC2a whereas the alternative pathway 
4 
convertase is formed by C3bBbC3b. C5b recruits complement components C6, C7, C8 and 
multiple C9 to form the terminal pathway component C5b-9, also known as membrane attack 
complex (MAC). 
The complement system is strictly controlled at several steps by complement regulators, 
which have been grouped into two categories: soluble and membrane-bound regulators
1
. C1 
inhibitor (C1INH) binds and inactivates C1r, C1s and MASP-2 in the classical and lectin 
pathway. Complement receptor 1 (CR1, also known as CD35), C4-binding protein (C4bp) 
and decay-accelerating factor (DAF, also known as CD55) dissociate the C3 and C5 
convertases. Moreover, factor H, membrane cofactor protein (MCP, also known as CD46), 
DAF and CR1 serve as cofactors for factor I mediated cleavage of C4b and C3b to their 
inactive fragments iC4b and iC3b. CD59 is expressed on most of cell types and blocks the 
assembly of MAC on cell membrane
3
. In addition, Factor P stabilizes the C3 convertase and 
is therefore the only known positive regulator of the complement system. 
As a central part of innate immunity, complement plays a key role in pathogens elimination 
and clearance of damaged cells. The process of covalent deposition of complement effectors 
such as C1q, C3 fragments (C3b/iC3b) and C4b on the target cell surface is called 
opsonization
1
. Opsonization accelerates the amplification loop of the complement pathways 
and promotes the phagocytosis of the opsonized cell (e.g. tumor cells, pathogens, apoptotic 
cells) by phagocytic cells such as neutrophils and macrophages. Complement anaphylatoxins, 
C3a and C5a, trigger the inflammatory response by activating immune cells via C3a receptor 
(C3aR) and C5a receptor (C5aR)
4
. Moreover, C3a and C5a play a critical role in the 
recruitment of immune cells with phagocytic properties.  
Complement activation terminates in the formation of the lytic MAC on the surface of 
invading pathogens, and is thus considered as a hallmark of the complement attack. In order 
to avoid accidental host cell damage, MAC formation is tightly regulated. For example, 
nucleated cells are protected from lysis by expression of CD59, which is known as the most 
important regulatory factor for MAC formation. For many years, the classical view of the 
MAC is the formation of membrane pore. However, lytic effects of MAC on nucleated cells 
are counteracted through the combination of complement surface regulators and activated 
recovery processes, resulting in the activation of host cells and proinflammatory signal 
transduction
5, 6
. 
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Figure 1. Complement activation cascade.  
The complement system is activated by three distinct pathways: the classical pathway, the alternative 
pathway and the lectin pathway. The classical pathway is activated through antigen-antibody 
complexes; the lectin pathway begins with the binding of MBL or Ficolins to carbohydrate ligands on 
the surface of pathogens and the alternative pathway initiates by spontaneous hydrolysis of C3. All 
complement activation pathways converge on the formation of C3 convertase and the subsequent 
generation of C5 convertase, which then cleaves C5 to anaphlatoxin C5a and C5b. C5b forms a 
membrane attack complex with C6, C7 C8 and multiple of C9. C1-INH inhibits the function of C1r, 
C1s and MASP2. CR1, C4bp and DAF can work as a co-factor for factor I to inactive C3b or C4b. 
Moreover, those factors can directly inhibit the C3 convertase function to negatively regulate 
complement activation. CD59 can disassemble the MAC formation. 
 
1.2 Terminal complement complex as a trigger for inflammation 
In principle, deposition of critical amounts of MACs disrupts the bilayer of the cell 
membranes, leading to cell lysis. However, next to gram-negative bacteria, only aged 
erythrocytes are susceptible to MAC induced cell lysis under physiological conditions
6
. MAC 
formation on nucleated cell membrane is tightly regulated and can be easily eliminated. 
CD59 is a 20 kDa glycolipid anchored protein which is expressed on most nucleated cells, 
and it binds tightly with C5b-8 to inhibit further recruitment of C9, consequently preventing 
MAC formation. Vitronectin is a 80 KDa glycoprotein and binds to the nascent C5b-7 to 
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produce water soluble C5b-7 (SC5b-7)
7
. This SC5b-7 is unable to further bind on the cell 
membrane but can bind C8 or three C9 molecules to form soluble C5b-8 or C5b-9, thereby 
limiting the generation of MAC pore on the membrane. Similarly, clusterin is another 70 kDa 
glycoprotein and it can interact with C7, C8 and C9b to block the assembly of C5b-7, C5b-8 
and C5b-9 respectively
8
. Moreover, ion pumps can counteract the lytic effects of MAC. For 
example, in rat oligodendrocytes, non-lethal complement attack led to reversible cell injury, 
recovery following a transient rise in intracellular calcium and fall in ATP
9
. Nucleated cells 
can also escape MAC lysis through endocytosis or membrane shedding
10
. 
Growing evidence indicates that sublytic levels of MAC create a variety of effects in different 
cell types
5, 11
. In Schwann cells, MAC has been shown to activate the small G-protein Ras 
and PI3K/AKT pathway to regulate cell cycle specific genes and promote cell proliferation
12
. 
Some research also reported that sublytic C5b-9 can trigger neutrophil and macrophage to 
synthesis and secrete inflammatory cytokines
5
. Furthermore, in retinal epithelial cells, MAC 
stimulates them to release interleukin-6 (IL-6), IL-8 and vascular endothelial growth factor 
(VEGF)
13
. MAC formed on human ECs can be rapidly internalized through clathrin-mediated 
endocytosis, and it can further activate proinflammatory functions via noncanonical nuclear 
factor-κB (NF- κB) signaling
14, 15
.  
Collectively, nucleated cells avoid MAC-mediated killing by diverse resistance mechanisms. 
Moreover, sublytic concentrations of MAC could activate pro-inflammatory signaling in 
many cell types
5, 9, 10, 13, 16
. 
 
1.3 Complement in cancer 
The complement system belongs to the innate immunity and is thus part of the classical 
pathogen defense
1, 6
. In that context, complement activation is triggered by pathogen-
associate molecular patterns and culminates in the formation of MACs on the surface of the 
invading pathogen
17, 18, 19, 20
. Nowadays, complement activation has been reported to enhance 
tumor progression and to increase metastasis suggesting its contribution beyond pathogen 
elimination
6, 21, 22
.  
Soluble complement factors are mainly produced in the liver and located in the blood. 
However, some cell types, like endothelial cell (EC), immune cells and fibroblast cells can 
produce complement proteins
21, 23
. Furthermore, it has been reported that complement 
7 
proteins produced by tumor cells can act in an autocrine manner to stimulate tumor growth 
through C3aR and C5aR mediated PI3K/AKT pathway
24
. During inflammatory and 
pathological conditions, deposition of complement fragments in tissue due to a boost 
complement production can be detected. 
Danger signals in tumor microenvironment for triggering complement activation have been 
reported by several studies recently. C1q has been shown to deposit along the tumor vessels 
and bind directly to the phospholipids in A549 and H157 lung cancer cells
25
. The damage 
associated molecular patterns (DAMPs) including modified glycolipids, glycoproteins and 
mucins exposed on the surface of tumor cells can trigger the complement activation in the 
tumor microenvironment
21, 26
. Natural or adaptive IgM antibodies against tumor associated 
antigens could also induce the complement activation
21, 27
. Surace et al. reported that 
radiotherapy induces local complement activation which is mediated by the IgM binding to 
necrotic tumor cells
28
. Moreover, in the tumor microenvironment, serine proteases like 
plasmin and thrombin cleave C3 and C5 directly, enhancing the complement terminal 
pathway activation via generation of the C3/C5 intermediates (e.g. C3a, C5a)
29, 30, 31
. 
Complement activation promotes chronic inflammation and supports an immunosuppressive 
tumor microenvironment. Markiewski et al. reported that C5a in the tumor microenvironment 
recruits myeloid derived suppressor cells (MDSCs) and induces the release of reactive 
oxygen species (ROS), resulting in the suppressing of antitumor CD8
+
 T cell-mediated 
response
32
. Consistent with these findings, C3a has also been reported to be implicated in 
tumorgenesis. In a spontaneous intestinal tumorgenesis mouse model, lipopolysaccharide, 
leaking from the intestine, was able to induce the complement activation and upregulation of 
C3aR on neutrophils
33
. C3aR-mediated signaling activation further polarizes neutrophils 
toward a pro-tumorigenic phenotype and triggers neutrophil extracellular traps (NETs)
33
. 
Recently, Wang et al. reported that in CD8
+
 tumor-infiltrating lymphocytes, autocrine 
complement C3 inhibits IL10 production via C3aR and C5aR, inhibiting IL10-dependent T 
cell mediated antitumor immunity
23
. In accordance with the idea of an immunosuppressive 
role of the complement, a combined blockade of the immune checkpoint molecule PDL1 and 
of complement receptors might be beneficial
34
.  
Apart from fuelling inflammation, a wealth of research has provided compelling evidence 
regarding the contribution of complement to the tumor growth. For example, C3a/C5a 
activate PI3K/AKT pathway to promote tumor cell proliferation
24
. Deposition of sublytic 
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levels of MAC on tumor cells induces cell cycle progression
35, 36
. Furthermore, C1q has been 
shown to support angiogenesis in the melanoma mouse model
37
. In line with that, 
complement activation correlates with poor outcome in cancer patients
38, 39, 40, 41
. 
Pharmacological blockade of complement related mediators or the deficiency of complement 
factors (e.g. C1q, C3) correlates with decreased tumor growth in experimental mouse 
models
23, 32, 33, 41
.  
 
1.4 Therapeutic regulation of the complement  
Complement activation mediates multiple roles in tumor progression, including promotion of  
chronic inflammation
42
, the establishment of an immunosuppressive tumor 
microenvironment
4, 21, 32
 and the activation of cancer growth signaling pathways
21, 24
. In this 
context, therapeutic manipulation of complement activation in tumor microenvironment has 
great potential. 
Eculizumab, an antibody against complement C5, is the first complement specific drug 
approved by the US Food and Drug Administration for the treatment of paroxysmal nocturnal 
hemoglobinuria (PNH)
43
 and atypical hemolytic uremic syndrome
44
. However, there are only 
very few clinical reports about the treatment with Eculizumab in cancer. Additionally, C5a 
has been shown to be a potent proinflammatory mediator in tumor microenvironment and 
contributes to the tumor growth
21
. C5aR antagonists, including PMX-53
22
 and AON-D21
34
, 
have been reported to inhibit tumor growth effectively in mice. Furthermore, combined 
blockage of PD-1/PD-L1 and C5a improves the antitumor immune responses and results in a 
substantial improvement in the efficacy of anti-PD1 antibody against lung cancer 
metastasis
23, 34
. 
Many complement factors interact with proteoglycans on the cell membrane or in the 
extracellular matrix and these interactions can be used for intervention of complement 
activation
45
. Notably, heparin and heparin related derivatives can be used for this purpose. 
Heparins are strongly related to the naturally occurring heparin sulfate, a major component of 
the endothelial glycocalyx. Low molecular weight heparins (LMWHs) are derived from 
unfractionated heparin by enzymatic or chemical depolymerization and used widely for the 
anticoagulant treatment. Coagulation and complement systems are evolutionarily related 
enzymatic cascades
29, 30, 31
. Interestingly, heparin is also demonstrated to have the anti-
9 
complement effects by many previous studies. For example, Girardi et al. showed that 
LMWH prevents antiphospholipid antibody induced fetal loss by inhibiting complement 
activation, rather than by their anticoagulant effects
46
. In the early studies, Wardle et al. 
confirmed that short-term administration of heparin could decrease 25% complement 
activation in nephritic patients
47
. Another study by Weiler et al. showed that treatment with 
heparin or N-acetyl heparin are effective to reduce cobra venom factor induced complement 
activation in guinea pigs
48
. A more recent research reported the inhibition of classical 
pathway via the interaction of LMWH with C1q in pregnant women
49, 50
. All of those studies 
showed the use of heparins as potential modulators of the complement system. 
Previous studies identified several anti-complementary effect mechanisms by heparin. For 
example, a lot of complement factors were found to be associated with the alteration of 
glycan profiles on the inflamed endothelium
45, 51
. Heparins can block those interactions and 
thus inhibit complement activation. Apart from this, heparin can inhibit the binding of C1q to 
immune complex and interfere the interaction of C4 with C1s and C2, blocking the initiation 
of classical pathway activation
46, 48, 52
. Furthermore, it has been reported that LMWH can 
inhibit the alternative pathway convertase formation by blocking the binding of C3b and 
factor B
46, 53
. LMWH could also inhibit complement mediated lysis of PNH red blood cells 
by the inhibition of C5b-6 binding to red blood cell membranes in vitro
46, 54
. 
Altogether, heparins can interact with multiple complement factors and a large body of 
research supports the use of heparin as inhibitor for complement activation. Imbalanced 
complement activation in the tumor microenvironment plays plenty of functions in tumor 
progression. Heparin based drugs targeting the complement envisions new therapeutic 
strategies in cancer therapy. 
 
1.5 Neutrophil in the tumor microenvironment 
Neutrophils, accounting for almost 50-70% of the white blood cells, are the first responders 
of defense against pathogens infection and tissue damage. Targeting microorganisms, 
neutrophils directly mediate host defense through phagocytosis and intracellular killing. In 
addition, neutrophils can also release granular antimicrobial protease and ROS or form NETs 
to trigger the innate immune response. Although neutrophils are well known for the host 
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protection, uncontrolled neutrophils activation potentiates chronic inflammation and tissue 
damage
55
.  
Many proinflammatory signals mediate neutrophil recruitment to damaged tissue or tumor 
site, including DAMPs, lipid mediators like LTB4, chemokines like CXCL1/2, cytokines like 
tumor necrosis factor α (TNF-α), IL17 and hydrogen peroxide
55, 56
. In addition, in the context 
of complement activation, immune cells such as neutrophils are recruited to the site of 
inflammation. The attraction of neutrophils is directly triggered by the chemoattractant 
anaphylatoxins C3a and C5a cleaved from the complement factors C3 and C5 as by-products 
of the complement cascade. Moreover, accumulation of the C3 fragments (C3b/iC3/C3c) on 
the endothelial surface promotes a rapid adhesion of blood-circulating neutrophils to the 
vessel wall
57
.  
Emerging evidence indicates a positive correlation between enhanced level of neutrophils and 
poor human tumor patient outcome
55, 56
. In the last years, a growing body of evidence 
indicated that neutrophils were educated by primary tumors in order to support the formation 
of metastasis in distant organs
55, 56, 58
. Importantly, neutrophil produced factors can directly 
enhance tumor proliferation and invasion, stimulate angiogenesis and induce 
immunosuppressive effects
55, 56
. For example, it has been reported that tumor related 
neutrophils can release granules containing neutrophil elastase and matrix metallopeptidase 
8/9 (MMP8/9) to remodel the extracellular matrix or modulate the inflammation in tumor 
microenvironment, supporting tumor progression and dissemination
55, 56, 59
. In addition, 
neutrophils can also release ROS to enhance tumorigenesis by inducing DNA damage and 
genetic instability
55, 56
. 
The tumor related microenvironment mediates activation of neutrophils and triggers the 
activation of oxidative burst, during which their NADPH oxidase gets activated to yield large 
amounts of superoxide
55, 60
. ROS contain superoxide, hydrogen peroxide and hydroxyl 
radical, which are generated by the reduction of O2 with a single electron, two electrons and 
three electrons in mitochondria respectively
61
. ROS not only mediate antimicrobial activity 
directly but also participate in stress signaling in normal cells
61
. In cancer cells, ROS amplify 
the tumorigenic phenotype by oxidizing nuclear or mitochondria DNA
60
. The released ROS 
are essential for the regulation of inflammatory response
61
. For example, ROS have been 
shown to regulate cell signaling pathway or trigger stress response in immune system to 
exacerbate or dampen inflammatory response
61
. Recent studies reported that neutrophil 
11 
released ROS inhibit CD8 T cell functions to create an immunosuppressive 
microenvironment
62
. It is interesting to note that those oxidant released from neutrophils can 
modify extracellular target and affect the function of surrounding cells, causing 
cytotoxicity
63
. ROS induce Ca
2+
 entry across the EC membrane and promote the formation of 
interendothelial gaps
64
.  
Tumor or complement mediated activation of neutrophil triggers also the release of NETs
55, 
65, 66
, which are large web-like extracellular structures composed of histones and neutrophil 
granule constituents that assembled on a scaffold of decondensed chromatin. This process, 
commonly called NETosis, occurs in response to infectious stimuli, sterile inflammation and 
cancer
65, 67
 and the release of the chromatin by neutrophils is dependent on the generation of 
ROS. ROS stimulate myeloperoxidase (MPO) to trigger the activation and the translocation 
of neutrophil elastase from granules to nucleus, resulting in histone degradation and DNA 
decondensation
68
.  
The molecular impact of those NETs is versatile and their functions not only limit to defense 
against pathogens but also contribute to cancer progression. There is evidence that NETs 
formed in the circulation provide a scaffold to promote cancer associated thrombosis
65
. In 
mouse models of cancer, NETs adhere to the endothelium and favor the arrest of circulating 
tumor cells, hence allowing tumor metastasis
33, 66, 67
. Moreover, NETs-associated histones 
and proteases can also be toxic for EC, contributing to vascular injury
59, 69
. Importantly, 
during NETosis, the released protumor factors, including MMP9, elastase, ROS can directly 
stimulate tumor cell proliferation and invasion
70, 71
. 
Complement and neutrophil are critical parts of the humoral and blood cell mediated innate 
immunity and many studies indicate the crosstalk between them
31
. C3a and C5a can recruit 
neutrophils to inflammatory site. Complement C3b opsonization on pathogens not only 
induces neutrophil phagocytosis but also facilitates NETs formation. Neutrophils in either C3 
or C3aR knock-out mice were not able to form NETs, suggesting the importance of the 
complement system for NETosis
33
.  
In addition, activated neutrophil can sever as a platform for complement activation
31
. 
Neutrophils activation under the treatment of LPS, TNF-α or PMA mediates the release of 
properdin, which binds to the membrane of neutrophil and initiates the alterative pathway 
activation
72
. Complement activation can also occur on released NETs
73
. Numerous 
complement factors, including properdin, C3, factor B have been reported to be deposited on 
12 
NETs
31, 74
. Additionally, granular proteases MPO and elastase that are present on NETs are 
able to directly cleave C3 or C5 in to their activated fragments
31
. 
 
1.6 Tumor endothelium 
Complement activation and Netosis can trigger EC activation and may be involved in vessel 
diseases such as vasculitits, thrombotic microangiopathy or tumor progression. However, the 
influential role of the crosstalk between complement and neutrophil on tumor endothelium 
dysfunction remains poorly understood and only few recent publications address this issue. 
Tumor cells rely on vascular network to get nutrition and oxygen, supporting their growth 
and dissemination
75
. In healthy tissue, endothelial monolayers are quiescent and the vascular 
endothelium maintains the regular blood flow by providing  a barrier to plasma and cell 
extravasation
75
. However, in the tumor microenvironment tumor cells secrete a variety of 
growth factors, especially VEGF, to stimulate EC proliferation and migration
76
. In addition, 
tumor ECs and the tumor cells utilize MMP9 to modulate the degradation of extracellular 
matrix, allowing tumor cells migration
77
. Multiple proinflammatory factors, like TNF, 
interleukin, ROS and complement related effectors can stimulate EC activation. Upon 
activation, ECs can upregulate cell adhesion molecules to capture or arrest circulating 
immune cells. For example, Albrecht et al. reported that C5a stimulates Human Umbilical 
Vein Endothelial Cells (HUVEC) showing progressive increases in gene expression for cell 
adhesion such as E-selectin, intercellular cell adhesion molecule 1 (ICAM-1), vascular cell 
adhesion molecule 1 (VCAM-1), and related receptors (VEGFC, IL-6, IL-18R)
78
. Similarly, 
the research from Wu et al. revealed that the complement component C3a activate 
phosphorylation of p38 mitogen-activated protein kinase (MAPK) and NFκB to induce 
murine primary cerebral ECs activation and the expression of adhesion molecules, such as E-
selectin and VCAM-1
79
. In addition, tumor associated changes of the endothelium have 
previously been linked to an altered proteoglycan expression at the EC surface
80, 81
. It has 
been reported that the expression of biglycan, a small leucine-rich-repeat proteoglycan, was 
specifically upregulated in highly metastatic tumor-derived EC
81, 82
. Interestingly, 
proteoglycans are able to accumulate different complement factors at the blood vessel wall 
and they are therefore also able to support localized complement activation
45
. 
13 
A prerequisite for metastasis formation is the change of vascular permeability, allowing 
tumor cells to cross the barrier. On the one hand, tumor cells can produce several factors to 
induce interendothelial junction disassembly, such as VEGF, IL-6, IL-8 etc. On the other 
hand, through binding on the adhesion molecules expressed on activated EC, activated 
neutrophil can mediate barrier dysfunction through the generation of ROS. A large body of 
literature indicated the oxidant induced endothelial structural alteration. Cytoskeletal 
remodeling by ROS leads to the disruption of endothelium barrier integrity and formation of 
paracellular gap. For example, HUVEC treatment with H2O2 results in the remolding of the 
actin microfilament network, from submembranous bundles into long transcytoplasmic stress 
fibers
83
. ROS can increase the level of intracellular Ca
2+
, which subsequently cause 
phosphorylation of myosin light chain, resulting in actin polymerization and enhanced 
endothelial permeability
84, 85
. Furthermore, MAPK and protein kinase signal pathway also 
take part in the oxidative stress mediated reorganization of the actin cytoskeleton
86
. 
ROS are also able to promote the release of NETs. NETs associated endothelial dysfunction 
is reported in many diseases, such as atherosclerosis, venous thromboembolism and systemic 
lupus erythematous
87
. Neting neutrophils secrete variety cytotoxic mediators that have been 
implicated in increased EC permeability. Neutrophil elastase and cathepsin G can digest VE-
cadherin and lead to the increase of EC permeability in vitro
88, 89
. Moreover, Carmona-Rivera 
et al. reported that MMP2/MMP-9 released from NETs specifically impaired murine aortic 
endothelium-dependent vasorelaxation and induced endothelial cell apoptosis
90
.  
 
1.7 Aims of study 
The role of the complement in protection against invasive pathogens through direct lysis and 
mobilization of adaptive immunity has been extensively studied. However, recent discoveries 
provide new perspectives on additional physiological roles of the complement in the tumor 
microenvironment. Complement activation derived effectors in tumors can promote tumor 
progression by creation of an immunosuppressive environment and by triggering tumor 
growth and metastasis.  
Melanoma is one of the most aggressive forms of skin cancer. High capacity of metastases is 
malignant melanoma´s main characteristics and melanoma is considered to be an 
immunogenic tumor. Although recent data demonstrate the contribution of several 
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complement effectors (such as C3a, C5a) to melanoma initiation
91, 92
, the distinctly different 
function for complement activation that might promotes melanoma metastasis has not yet 
been explored. Therefore, the present study aims to investigate the activation status of the 
complement system in melanoma and the impact of activated complement on malignant 
behavior of melanoma. 
Complement system and neutrophil are two major effectors of humoral and blood cell 
mediated innate immunity. Neutrophils are the first responder recruited to the site of 
inflammation under a variety of signals including lipid mediators, chemokines and C3a and 
C5a. Released from activated neutrophils, ROS and NETs-associated histones and proteases 
can be toxic for EC, resulting in vascular injury. A growing body of evidence indicates the 
crucial involvement of neutrophil in tumor cell dissemination. A prerequisite for metastasis 
formation is the dysfunction of the endothelium, followed by tmelanoma cells extravasation. 
Notably, many reports suggest a connection between complement and neutrophil activation. 
However, so far, data on the triangular crosstalk between the complement, neutrophils and 
the endothelium within the tumor microenvironment are scarce. Here, we used distinct mouse 
models and human tumor tissues to study complement activation, the functional relevance of 
complement activation on neutrophils and ECs and the impact on melanoma cell 
dissemination.  
The activity of many complement factors is controlled by their interaction with heparan 
sulfate exposed on the EC surface
45
. Intervention of these interactions can attenuate 
complement activation and heparin sulfates related LMWH has previously been used for this 
purpose
45
. Additionally, our previous work has shown that tinzaparin treatment attenuated 
tumor progression and metastatic burden in murine animal models
93, 94
. Therefore, our study 
also investigated the impact of LMWH on complement activation and the crosstalk between 
neutrophils and the endothelium.
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2 Methods 
2.1 Chemicals and tissue culture materials 
All general chemicals are commercially available analytical reagents and were purchased 
from Sigma, Roth, Merck, Neolab and Biozym. Cell culture reagents were purchased from 
Invitrogen, PAA, Lonza and Sigma. Cell culture materials were from BD. The information 
about important reagent is shown in the following method description. 
 
2.2 Antibodies 
Product Description Company Catalog  NO. 
mouse anti-human C3b/iC3b  Hycult HM2286 
rabbit anti-human VWF  Dakocytomation A0082 
mouse anti-human CD15 Abcam Ab188610 
rabbit anti-human TCC-FITC Hycult HM2167F 
rat anti-mouse C3b/iC3b/C3c Hycult HM1065 
rat anti-mouse CD31 BD Bioscience 550274 
rabbit anti-mouse C5a Biorbyt Orb10213 
rat anti-mouse ly6g BD Bioscience 551459 
rabbit anti mouse C5b-9-FITC Biobyt Orb102206 
rabbit anti-human Histone H3 Abcam Ab5103 
GAPDH loading control antibody Thermo MA5-15738 
goat anti-mouse IgG-HRP Santa cruz Sc2005 
rat anti-mouse C1q Hycult HM1044 
Mouse anti-human C9 Santa cruz Sc390000 
Rat anti-mouse F4/80  BD Bioscience 565409 
Hamster anti-mouse CD11c-APC  Biolegend 117310 
Rat anti-mouse CD3 BD Bioscience 555273 
Rabbit anti-mouse Factor B  Lifespan 114998 
Rat anti-mouse C4  Hycult HM1046 
Rat anti-mouse MBL-C Hycult HM1038 
Goat anti-mouse SDC1  R&D AF3190 
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FITC-conjugated goat anti-rat BD Pharmingen 554016 
FITC-conjugated goat anti-rabbit BD Pharmingen 554020 
Alexa® 555-conjugated goat anti-rat Invitrogen A21434 
Alexa® 555-conjugated goat anti-rabbit  Invitrogen A21428 
Alexa® 555-conjugated goat anti-mouse (IgG) Invitrogen A21422 
Alexa® 555-conjugated goat anti-mouse (IgM) Invitrogen A21426 
Alexa® 647-conjugated goat anti-rabbit Invitrogen A21244 
 
2.3 Kits 
Product Description Company Catalog  NO. 
Human C5a ELISA Kit R&D DY2037 
Human C3a ELISA Kit Hycult HK354 
Human C3 ELISA Kit Abcam Ab108822 
Human C3b ELISA Kit Abcam Ab195461 
Pierce® BCA protein assay kit Thermo 23225 
SuperSignal™ West Pico PLUS 
Chemiluminescent Substrate 
Thermo 34580 
RNeasy Mini Kit QIAGEN 74106 
Reverse Transcription System Promega A3500 
GoTaq® qPCR Master Mix Promega A6001/2 
Cell Death Detection ELISA Roche 11920685001 
 
2.4 Cell lines and cell culture 
The human melanoma cell lines (WM9, MV3 and IGR37) were cultured in DMEM (Gibco, 
Life Technologies) with 10% FBS. Human melanoma cell lines (BCL, WM3211, Mel-6, SB-
CL-2, BLM, WM4511 and G361) were cultured in RPMI-1640 (Gibco, Life Technologies) 
with 10% FBS. Mouse melanoma cell lines Ret were cultured in RPMI-1640 (Gibco, Life 
Technologies) with 10% FBS, 1% non-essential amino acids (Sigma) and 1% L-Glutamine. 
Mouse melanoma cell lines B16 were cultured in DMEM (Gibco, Life Technologies) with 
10% FBS, 1% NEAA (Sigma) and 1% L-Glutamine. 
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HUVEC were isolated from donor umbilical cord according to the ethical regulation (Ethics 
committee, University medical Centre Mannheim, Germany) and were cultivated in the 
Endothelial Cell Growth Medium (Promocell, C-22010) supplemented with SupplementMix 
(Promocell, C-39215). The HUVEC isolation was done using our lab established protocol. 
All cell lines were cultured in humidified incubator at 37°C in a humidified 5% CO2 
atmosphere. The cells were passaged at a confluency of about 90% according to stander 
protocol. 
 
2.5 Mouse procedures  
All animal experiments were approved by the government animal care authorities and mice 
were maintained under specific pathogen free conditions. C57BL/6J wild type and C5-
deficient mice were purchased from the Jackson Laboratory, backcrossed as previously 
reported 
95
. 7.5×10
5
 ret transgenic melanoma cells in 100 µl PBS per mouse were i.d. injected 
into 8-12 week old mice. After 15 days, mice were sacrificed and tumors were embedded in 
Tissue Tek
®
 for cryosectioning. 5×10
5
 B16F10 melanoma cells in 100 µl PBS were 
intravenously injected into the tail veins of mice to induce lung metastases. The mice were 
sacrificed after 14 days, and the metastatic lungs were dissected and photographed. 
For heparin treatments, Tinzaparin (600 IU/kg) dissolved in 100 μl NaCl were 
subcutaneously injected into the mice to check the effect of anti-complement on tumor 
progression. The application took place the first day before the injection of melanoma cells, 
then daily until the day of scrification (2 weeks). Control mice were injected with 100 μl of 
physiological saline. For anti-NETs therapies, Cl-amidine (10mg per kg body weight; 
Millipore) or PBS was injected intraperitoneally on days 12, 13, 14 and 15. The intradermal 
tumor was excised and immediately embedded in in Tissue Tek
®
, placed on dry ice and snap-
frozen at -80 ° C. 
 
2.6 Human malignant melanoma patients’ plasma and tissue 
EDTA-plasma samples and melanoma tumor tissues were obtained from stage UICC IV 
malignant melanoma patients. Skin tumors tissue samples were obtained from the department 
of human pathology, UKE, Germany. This study received the approval from the ethics 
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committee of the Medical Faculty of Mannheim, Heidelberg University and the University 
Medical Center Hamburg-Eppendorf. 
 
2.7 Tissue immunofluorescence staining  
10 µm frozen sections were prepared with a microtome, and the sections were stored at -20 
°C until staining. This staining was a two-step method: First, a primary antibody binds 
specifically to the structure to be detected. Then, a second antibody labeled with a fluorescent 
dye binds to species-specific epitopes on the primary antibody. As a result, the cell structures 
were stained indirectly.  
Tissue cryosections (10µm) were fixed in 4% PFA for 15min, and then washed with PBS and 
blocked with 10% goat serum for 30 min. After a single wash with PBS, the cryosections 
were incubated with primary antibody for two hours in room temperature or 4 °C overnight. 
Negative controls sections were incubated only with PBS-T to recognize non-specific binding 
of the secondary antibody. After washing three times with PBS-T, the slides were incubated 
with secondary antibody diluted in 10% goat serum for 1 hour in room temperature. In order 
to stain the second cell structure, the sections were washed again three times with PBS-T, 
blocked for 30 min, and then the above procedures were repeated with corresponding 
antibodies. Nuclei were stained with DAPI (Sigma). FITC–conjugated wheat germ agglutinin 
(WGA, sigma) were used to stain glycocalyx. Finally, the tissue sections were washed 
thoroughly with PBST, and slides were mounted with mowiol-DABCO (0.5ml Mowiol4-88 + 
25mg DABCO) (Sigma) by coverslips. The staining was viewed with Zeiss Axiovert 200 
microscope. Images were processed with Axio Vision software and Image J. 
 
2.8 Immunofluorescence cell staining  
Prior to immunofluorescence staining, ECs were seeded on 10% gelatin coated coverslips in a 
12-well plate. This was followed by stimulation of the ECs according to the procedure 
described below. Subsequently, the cells were washed with PBS and fixed in 4% PFA for 10 
min, and then washed with PBS and blocked with 10% goat serum for 30 min. Appropriate 
antibodies were used for the following staining procedures, which were same according to 
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tissue immunofluorescence staining protocol described above. After the final washing step, 
coverslips were mounted on glass slides and viewed with microscope. 
 
2.9 ELISA assay 
ELISA was performed in accordance with the instructions of the manufacturer. BioTek 
PowerWave XS2 Photometer was used to determine the optical density of each well at the 
wavelength of 450 nm. The relative amounts of C3, C3 fragments, C3a and C5a were 
calculated basing on the standard curve generated according to the respective manufacturer’ 
protocols. 
 
2.10 RNA extraction and qPCR 
RNA was extracted by using RNeasy Plus Mini Kit (Qiagen), and cDNA was synthesized by 
using Reverse Transcription System (Promega). qPCR reactions (GoTaq® qPCR Master 
Mix, Promega) were performed using a real-time PCR system (Light cycler 96 system, 
Roche). The expression of each gene was normalized to its housekeeping gene GAPDH, 
calculated by 2^
(-ΔΔCt)
. The expression profile of the different cell populations was shown in a 
heat map. Primers can be found in attached table.  
 
CD46-FP (Gene ID:4179) AAGTGGTCAAATGTCGATTTCCA 
CD46-RP (Gene ID:4179) TCGAGGTAAAAACCCTTATCGC 
CD55-FP (Gene ID:1604) AGAGTTCTGCAATCGTAGCTGC 
CD55-RP (Gene ID:1604) CACAACAGTACCGACTGGAAAAT 
CD59-FP (Gene ID:966) CAGTGCTACAACTGTCCTAACC 
CD59-RP (Gene ID:966) TGAGACACGCATCAAAATCAGAT 
FactorP-FP (Gene ID:5199) TGCTCTGCTTCACCCAGTATG 
FactorP-RP(Gene ID:5199) CCACTACGTTTCTGGTAGGCA 
GAPDH-FP (Gene ID:2597) GGAGCGAGATCCCTCCAAAAT 
GAPDH-RP (Gene ID:2597) GGCTGTTGTCATACTTCTCATGG 
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2.11 Neutrophil isolation  
Blood was drawn from healthy donors into EDTA coated tube. Neutrophil isolation was 
performed by using Histopaque-1119 (Sigma) and Percoll Plus (GE Healthcare) gradients as 
described
96
, which cause minimal neutrophil activation during isolation
97
. 6 ml Histopaque-
1119 was added to a 15 ml Falcon tube and 7 ml whole blood was carefully added on the top 
of Histopaque. After that, tube was centrifuged for 20 min at 800g without braking. Attached 
Figure 1 shows the tube after centrifugation and we can find four different layers from up to 
down - plasma, PBMC, neutrophil mixed with erythrocytes and erythrocytes layer. 
 
Figure 1. Falcon tube after the first time of 800 × g centrifugation.  
7 ml whole blood was carefully added on the top of 6 ml Histopaque and the tube was centrifuged for 
20 min at 800 × g without braking. After centrifugation, four different layers can be observed. 
 
Next, the plasma and PBMC layers were discarded and only the reddish neutrophil layer was 
transferred into a fresh Falcon tube. Cells were washed with 10 ml PBS and mixed by 
inverting the capped tube 5 times, and then centrifuged for 10 min at 300 g. At the meantime, 
2 ml 10 × PBS was added to 18ml 100% Percoll and mixed it by inverting the capped tube 
several times. 85 %, 80 %, 75 %, 70 % and 65 % Percoll were prepared according to 
following table. 
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 85 % Percoll 80% Percoll 75% Percoll 70% Percoll 65% Percoll 
Mixed Percoll 3.4ml 3.2ml 3ml 2.8ml 2.6ml 
1 × PBS 0.6ml 0.8ml 1ml 1.2ml 1.4ml 
 
After that, Percoll gradient was performed in a new Falcon tube by layering 2 ml of different 
percentage Percoll on top of each other in decreasing order. This procedure should be done 
carefully and slowly. Cell pellets after 300g centrifugation were resuspened in 4 ml of PBS 
and then 2 ml of the cell resuspension was added on the top of Percoll gradient carefully. 
After that, centrifuge for 20 min at 800 × g without braking. Attached figure2 shows the tube 
after centrifugation and neutrophils rich layer was found at the 80% Percoll phase (red 
arrow). After centrifugation, discared top and 65% layer and collected remaining lyers until 
85% layer into new tube. Neutrophils were washed with 10 ml PBS and mixed by inverting 
the capped tube 5 times, and then centrifuged for 10 min at 300 g. After centrifugation, the 
supernatant was removed and 2 ml RPMI was used to resuspend the sedimented neutrophils. 
Normally, we can isolate 1 × 10
7
 neutrophils from 7 ml blood. RPMI was used as the basic 
medium for following neutrophil in vitro experiments. 
 
Figure 2. Falcon tube after the second time of 800 × g centrifugation.  
2 ml of the neutrophil resuspension (in PBS) was added on the top of Percoll gradient carefully and 
the tube was centrifuged for 20 min at 800 × g without braking. Red arrow showed the neutrophil rich 
layer after centrifugation. 
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2.12 Complement activation on ECs and co-culture with neutrophil 
HUVEC were seeded on 10% gelatin coated coverslips in a 12-well plate. After the cells 
reached to subconfluency, cells were sensitized by CD31 antibodies (DAKOCytomation, 
1:50 dilution, 20 min). Antibody-labeled HUVECs were washed with PBS and then exposed 
to 10% normal human serum (NHS) for 15 min. After that, non-sensitized neutrophils 
(1×10
5
) co-cultured with HUVEC. After 30 min incubation, MAC formation was analyzed by 
immunofluorescence cell staining. 
 
2.13 In vitro sublytic MAC formation and detection on neutrophil 
The induction of sublytic MACs on neutrophils was performed as described by B.P. 
Morgan
10
. Briefly, anti-human CD15 antibody (Abcam, 1:100 dilution, 15 min) was used to 
sensitize neutrophils and then neutrophils were washed with PBS and exposed to 10% NHS 
to induce MACs formation. Heat inactivated serum (56°C for 30min; HIS) and C5-depleted 
serum were used as negative controls. 
For the detection of in vitro MAC formation on neutrophils, antibody sensitized neutrophils 
were exposed to 10% of NHS or HIS for 30 min first and then cells were washed 3 times with 
PBS. For western blot detection, neutrophils were resuspended in cold lysis buffer containing 
Complete
TM
 protease inhibitor cocktail (Roche). 20µg of protein was separated by sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and western blot was 
performed according to standard protocols using monoclonal antibody to C9 (Santa Cruz, 
1:50) for detection. 
 For FACS detection, cells were washed with PBS and then incubated with rabbit anti-human 
TCC-FITC antibody (Hycult, 1:100) for 30 min and acquisition was done using FACS Canto 
II (BD bioscience). FACS was performed according to standard protocols. 
 
2.14 ROS detection 
MAC mediated intracellular ROS production was measured with dichlorofluorescindiacetate 
(DCFDA, Sigma). Neutrophils were stained with 20 μM DCFDA at 37°C for 30 min. Then 
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neutrophils were washed once, and the dichlorofluorescein (DCF) level was evaluated by 
microscope (Axiovert 200, Zeiss) or flow cytometer (FACS Canto II, BD).  
Luminol chemiluminescence was used to monitor the kinetics of the MAC induced ROS 
production. Prior to Luminol-Assay, the following reagents were prepared. 
 Luminol (Sigma) stock solution, in DMSO: 0.25 mol/L (50×) 
 P-coumaric acid (Sigma) stock solution, in DMSO: 0.09 mol/L (50×) 
 Neutrophil suspension in Medium RPMI (Gibico): 2 × 106 /ml 
 Mastermix for stimulation, based on medium RPMI. 
o Luminol: 5 mmol/L 
o P-coumaric acid: 1.8 mmol/L 
PMA (Sigma) was used as postive control. Luminescence measurement was performed on 96 
white wells plate (BRANDplates
®
). 50 µl neutrophil suspensions was added in each well first 
and then incubated with 50 µl Mastermix in each well. After adding the Mastermix, 
luminescence was measured immediately on Tecan M200 microplate reader. 
Final concentrations per well (100 µl) during stimulation: 
o Luminol: 2.5 mmol/L 
o P-coumaric acid: 0.9 mmol/L 
o PMA 0.1 µg/ml (Positive control) 
o 1× 105  neutrophils per well 
 
2.15 DNA-Histone fragments detection   
Antibody sensitized neutrophils were treated with 10% NHS, HIS, C5 deplete serum and 
NHS with the addition of tinzaparin (100IU/ml) for 3 hour. The supernatants were collected 
and centrifuged to remove cell debris. Histone-associated DNA fragments were quantified by 
the ELISA Kit (Roche) following the manufacturer’s protocol. Citrullinated histone H3 
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(H3Cit) in supernatants was evaluated by Western Blot using the antibody from Abcam. 
Western Blot was performed according to standard protocols. 
 
2.16 Neutrophil stimulation by C5a 
Isolated neutrophils were incubated with human recombinant C5a (100ng/ml, R&D) for 
30mins and then FACS was used to check the changes for neutrophil morphology and ROS 
production. C5a stimulated neutrophils were treated with HIS or NHS for 1 hour. MAC 
formation was checked by FACS and the neutrophil supernatants were collected for the 
analysis of NETs. 
 
2.17 MACs and NETs staining 
Neutrophils treated with NHS, HIS or NHS with the addition of tinzaparin (100IU/ml) for 30 
min. Cytospin (Shandon
®
) was used for the preparation of neutrophil for microscopy. 
Neutrophils were fixed with 4% PFA for 10 min. Anti-human MAC-FITC antibody (Hycult) 
and anti-human anti-citrullinated histone H3 antibody (Abcam) were used for the MACs and 
NETs immunofluorescence staining. DAPI was used to stain the nuclei and the released 
DNA. 
 
2.18 EC layer integrity staining 
HUVEC were seeded on 10% gelatin coated coverslips in a 12-well plate one day before the 
experiment. After the HUVECs reached to 100% confluence, HUVEC co-cultured with MAC 
positive neutrophils and control neutrophils (5×10
5
 per well) for 6 hours. After one time wash 
with PBS, HUVEC was fixed with 4% PFA for 10 min, and blocked with 2% BSA for 20 
min. Mouse anti-human CD31 (DAKO Cytomation) and DAPI were used for following 
staining. 
 
2.19 Electric Cell-substrate Impedance Sensing (ECIS) 
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The trans-endothelial electrical resistance (TEER) of an ECs monolayer was measured by 
ECIS, using established protocols
98
. Briefly, HUVECs were grown to confluence on gelatin 
coated gold electrodes, and then co-cultured with MAC positive neutrophils (1×10
5
 per well) 
or untreated control neutrophils as described above. The real time changes in TEER were 
measured, and data was presented as change in HUVECs layer resistance normalized to value 
at the beginning time for the co-culture. For the inhibition of NETosis, MAC-neutrophils 
were co-cultured with HUVECs in the media containing Tinzaparin (100IU/ml) or DNase I 
(100U/ml, sigma) or Cl-amidine (50µM, Millipore). 
 
2.20 Human melanoma cells transmigration assay  
Melanoma cells transmigration assay was performed as described previously
99
. MAC positive 
neutrophils or control neutrophils (1× 10
5
 per well) co-cultured with confluent HUVECs for 6 
hours in the cell culture inserts (24 well plate, Greiner Bio-one) and then the neutrophils were 
removed by washing with PBS. Human melanoma MV3 (1× 10
5
 per well) was labeled by 
Celltrace calcein green (Invitrogen) and then added to the upper chambers. After 12 hours, 
microscope was used to detect the migrated labeled cells. 
 
2.21 Complement assay 
The effect of tinzaparin on the haemolytic activity of the classical pathway (CH50) and the 
alternative pathway (APH50) was assessed according to the described procedures by 
Wehling
100
and Joiner
101
et al. The CH50 tests the total hemolytic activity of the classical and 
terminal pathways by human serum, and this method depends upon lysis of sheep red blood 
cells pre-coated with rabbit anti-sheep red blood cell antibody. Like the CH50 assay, the 
APH50 assay measures the total alternative pathway hemolytic activity to lyse unsensitized 
chicken erythrocytes by human serum. Results were showed in reference to a pool of normal 
human serum as standard (100%). The reagents and devices were provided by Prof. Dr. 
Kirschfink and this experiment was done in their lab (Institute for Immunology, University of 
Heidelberg, Heidelberg, Germany). 
 
2.22 Statistical analysis 
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Statistical analysis was performed with GraphPad Prism 6 software and significance was 
tested by Student’s t-test. All results are presented as the means ± standard error as indicated 
in the legend. P< 0.05 was considered as significant difference. 
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3 Results 
3.1 The complement system is activated in human malignant melanoma. 
To investigate the activation status of the complement system in melanoma patients (stage 
IV), we measured the levels of C3 in blood samples by ELISA (Figure 1A). In healthy 
controls, the mean plasma level of C3 was 2210 ± 81.75μg/ml. In cancer patients C3 was 
significantly decreased to 1665 ± 155.3μg/ml. This result suggests the consumption of C3 due 
to the activation of the complement system. C3 plays a central role in the complement 
cascade activation and its activation is required for both classical and alternative pathways. 
Therefore, we further analyzed the C3 derived fragments C3a and C3b (Figure 1B-C). The 
concentration of C3a in healthy control was 263.3 ± 9.6ng/ml, this was significantly 
increased to 301.3 ± 9.3 ng/ml in melanoma patients (Figure 1B). Similarly, the mean plasma 
level of C3b in healthy controls was 1059 ± 24.7μg/ml and increased to 1175 ± 24μg/ml in 
melanoma patients (Figure 1C). C3a is an inflammatory mediator and recruits immune cells 
to inflammatory sites. The increased concentrations of C3 cleavage products in the plasma of 
cancer patients confirm the melanoma-related complement activation. In both classical and 
alternative pathways, C3b binds to the C3 convertases (C4b2a  and C3bBb) to form C5 
convertases, which cleave C5 to produce C5a and C5b.To further prove the activation course 
of the complement cascade, we measured the plasma levels of C5a (Figure 1D). In line with 
the supposed activation of the complement system, C5a levels were significantly elevated to 
1354 ± 137.8pg/ml in melanoma patients compared with 989.9 ± 88.9pg/ml for the controls. 
C5a is the downstream product of the C3b-catalized cleavage of C5 during the complement 
activation. C5a plays critical role in supporting inflammation by the mobilization of immune 
cells and activation of cells expressing C5a receptors. 
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Figure 1. Quantification for complement effectors in plasma samples from control donors and 
melanoma patients. 
Systemic complement effector levels in plasma samples from control donors and stage IV malignant 
melanoma (MM) patients (A-D) were analyzed by ELISA. C3 levels in blood samples of MM patients 
were decreased compared with healthy control donors (A). In contrast, C3 activation fragments C3b 
and anaphylatoxins C3a and C5a were increased in the plasma of cancer patients (B-D).*P< 0.05, 
**P< 0.005. 
 
3.2 Complement activation fragments deposit in human melanoma tissue. 
To support our ELISA data, we evaluated the presence of C3 fragments C3b/iC3b in 
cryosections of human malignant melanoma tissues (n=5, stage IV). Healthy skin was used as 
control tissue. To this end, tumor cryosections were stained for C3b/iC3b and Von 
Willebrand factor (VWF), and VWF was used as endothelial cell marker. 
Immunofluorescence analysis revealed that C3b/iC3b colocalized with the endothelium of 
tumor blood vessels suggesting the deposition of C3 fragments on the vessel wall and thus 
complement activation around the vasculature (Figure 2A, right). C3 fragments deposition 
was scarcely present in healthy skin, which was used as control tissue (Figure 2A, left), 
indicating the quiescent complement activation in healthy tissue. The corresponding 
quantification revealed that only 4.9% of vessels in healthy skin contained C3 fragments, and 
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this was significantly increased to 12.1% in the human melanoma tissue (Figure 2B). Because 
the complement cascade terminates in the formation of the MAC, we further analyzed the 
presence and localization of this terminal complex in the tumor tissue. To our surprise, we 
could not detect significant levels of MAC at the endothelium (date not shown); however we 
discovered that about 52% of all tumor-related neutrophils were MAC positive (Figure 2C-
D). In healthy skin, not so many neutrophils were found and most of those neutrophils were 
MAC negative.  
 
Figure 2. Complement activation in human malignant melanoma patients. 
Immunofluorescence analysis of C3b/iC3b (A) or CD15 and MAC (C) in cryosections (scale 
bars=20µm) of human MM tissues (stage IV, n=5) and healthy skins was performed; VWF was used 
as blood vessel marker. Nuclei were stained with DAPI. Representative images of melanoma tissue 
show the blood vessel associated deposition of C3b/iC3b whereas analysis of healthy skin indicates 
the absence of C3 fragments (A). Quantification revealed significantly increased numbers of vessels 
with C3b/iC3b deposition in tumors compared with healthy skin (B). MACs were detectable on 
neutrophils in tumor tissue whereas no MACs were formed on healthy skin neutrophils (C). 
Neutrophils with or without MACs were quantified and the number of MAC positive neutrophils were 
significantly increased compared with healthy skin (D). Bars indicate the mean ± SD, **P< 0.005, 
***P< 0.0005. 
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3.3 MACs deposit on neutrophils in murine tumors. 
The results from the human samples suggest that the melanoma microenvironment promotes 
complement activation. Moreover, the finding of strongly elevated levels of MAC+ 
neutrophils in the tumor tissue indicates a crosstalk between the humoral complement system 
and the cell mediated neutrophil innate immunity. To further investigate the impact of the 
complement system on melanoma progression and the potential connection to neutrophil 
activation, we checked the levels of different complement factors by immune fluorescence in 
tissue sections of primary tumors generated by the intradermal injection of human ret 
transgenic murine melanoma cells into the dorsal skin of mice.  
In line with the human melanoma tissue, C3 cleavage products (C3b, iC3b and C3c) were 
extensively deposited along almost 30% of the tumor vessels, indicative of an activate 
complement environment around tumor vessels, whereas deposition of those C3fragments 
was absent in control skin (Figure 3A-B). Recently, it was shown that blood vessels in early 
staged melanomas (1 week tumor) retained only neglectable amounts of C3 fragments. We 
confirmed these previous findings in our melanoma model, indicating that complement factor 
deposition and complement activation is related to advanced melanomas (Figure 3C). The 
anaphylatoxin C5a, a potent immune mediator and neutrophil attractant protein was also 
elevated in the proximity of tumor blood vessels when compared to healthy skin (Figure 3D-
E). In correlation with the increased C5a levels, we also found the recruitment of neutrophils 
to C5a rich areas (Figure 3F). In addition, we analyzed the staining of MACs, and in analogy 
to our human tissue analysis, we found MACs deposited not on the endothelium but on 
neutrophils (Figure 3G). Quantification revealed almost 85.1% of tumor-associated 
neutrophils exhibited positive MAC (Figure 3H). In summary, our findings suggest that the 
complement cascade is initiated on the endothelium, whereas the terminal MACs is 
established on adjacent neutrophils. 
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Figure 3. Immunofluorescence analysis of complement components in mouse engrafted tumor.  
Cryosections (n=5, scale bars=20µm) from mice primary tumors were stained for VWF and C3 
cleavage products (C3b, iC3b and C3c) (A, C) or CD31 and C5a (D) or Ly6g and MAC (G). Nuclei 
were stained with DAPI. In healthy mouse control skin, no complement effectors (C3 fragments, C5a, 
MAC) were detected, indicating a quiescent complement milieu (A, D, G left). Representative images 
of mice melanoma show that C3 cleavage products were deposited along the tumor vessels (A). 
Quantitative analysis demonstrates an increased number of tumor blood vessels with C3 fragment 
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deposition, as compared with healthy skin control (B). Immunofluorescence staining show that no 
obvious C3 cleavage products (C3b/iC3b) deposit on the vessels walls in cryosections of 1 week 
mouse melanoma tumors (C). C5a shows a punctuate staining in the proximity of blood vessels (D) 
and quantification revealed a significantly increased number of vessels with C5a accumulation (E). 
Neutrophils were recruited to C5a rich areas of the tumor (F, Scale bar=50µm) and MACs deposited 
on tumor associated neutrophils (G-H). Bars indicate the mean ± SD, *P< 0.05, **P< 0.005, ***P< 
0.0005. 
 
3.4 Complement activation occurs locally in tumor. 
To further investigate whether the complement activation occurs systemically or only locally, 
we checked the complement activation status in the peripheral organs of tumor bearing mice. 
We were not able to detect an enhanced C3b/iC3b deposition in the vasculature of other 
tissues (e.g. kidney, lung and liver; Figure 4A) except in tumors. So, local tumor-specific 
complement activation appeared to be evident. In further control experiments regarding 
MACs location, we detected MAC deposition neither on tumor associated macrophages, 
dendritic cells and T Cells (figure 4B) nor on neutrophils in mouse peripheral organs such as 
lung, liver and kidney (figure 4C), confirming that the MAC forms only on tumor-associated 
neutrophils. 
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Figure 4. Complement factor deposition in murine tissues.  
Kidney, lung and liver tissues were obtained from melanoma bearing animals (n=4 each). 
Cryosections were stained for VWF (green) and C3 cleavage products (C3b/ iC3b, red) (A) or MAC 
(green) and Ly6g (red) (B, C). No C3 cleavage product deposition and MAC positive neutrophils 
were observed in the peripheral organs (A, C). MAC was neither formed on tumor associated 
macrophages (F4/80 staining, red), T cells (CD3 staining, red) nor in DC (CD11c staining, red) (B). 
 
3.5 The lectin pathway is predominantly involved for the complement activation. 
To clarify which of the complement pathways contributed to the measured production of 
anaphylatoxins and the formation of MACs, we compared the endothelial expression of C1q, 
MBL and factor B (Figure 5A). Lack of factor B deposition on the tumor endothelium 
suggested a negligible contribution of the alternative pathway. In line with the previous work 
published by Bulla et al
37
, we were able to detect C1q at the blood vessel wall. However, we 
also detected a considerable amount of blood vessels positive for MBL. Through 
quantification of tissues sections of 5 different melanomas we found that about 25% of the 
blood vessels were positive for MBL whereas only 12% of the blood vessels were C1q 
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positive indicating that the lectin pathway is mainly responsible for the complement 
activation (Figure 5A). Conform to the supposed activation of the classical and especially the 
lectin pathway we found the deposition of C4 as well (Figure 5A). The MBL recognizes 
pathogen-associated carbohydrate structures rich in mannose, N-acetylglucosamine or 
glucose
2
. Although those carbohydrates are not exposed by healthy mammalian cells, a 
growing body of evidence indicates that under pathophysiological conditions an aberrant EC 
glycosylation allows the binding of MBL
2, 102
. Interestingly, the function of various 
complement factors is tuned by their interaction with carbohydrates. For instance, the binding 
of factor P to specific epitopes of heparan sulfate has been shown to initiate alternative 
pathway activation
51
. To further clarify whether the endothelial glycosylation controlled the 
tumor blood vessel wall restricted complement activation, we correlated the C3b/iC3b 
deposition with the endothelial expression of N-acetylglucosamine, a major component of 
heparan sulfate. N-acetylglucosamine was stained by wheat germ agglutinin (WGA). As 
shown in Figure 5B, deposition of C3b/iC3b along the blood vessel wall co-localize with the 
WGA staining. Quantifications reveal that significant more C3b/iC3b deposited on WGA 
positive blood vessels. In line with the WGA staining, deposition of C3b/iC3b correlated also 
with increased levels of the heparan sulfate exposing proteoglycan syndecan 1 (SDC1) 
(Figure 5C).This data suggest that an aberrant glycosylation of the tumor EC may trigger 
complement activation.  
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Figure 5. Proteoglycan induces the restricted complement activation on tumor vessel walls. 
Immunofluorescence stainings of early complement components (C1q, MBL, FB (Factor B) and C4) 
were performed (scale bars=20µm). Quantification indicates a comparable high abundance of MBL 
positive vessels. Less are positive for C1q. Blood vessel wall deposition of factor B was not 
detectable (A). Cryosections of primary tumors were stained for WGA (green), VWF (white), C3 
cleavage products (C3b/ iC3b, red) and nuclei were stained with DAPI (blue) (B). Representative 
image and quantification showed C3 fragment deposition on blood vessels with high levels of N-
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acetylglucosamine (B). Immunofluorescence staining of SDC1 (red) and C3b/iC3b (green) in 
cryosections obtained from mouse melanoma tumors (C, scale bars=20µm, n=4). Quantification 
shows that higher levels of SDC1 expression were accompanied by enhanced C3b/iC3b deposition 
(C). Bars indicate the mean ± SD, *P< 0.05, **P< 0.005. 
 
3.6 MACs form on neutrophils in close proximity to the tumor. 
Our ex vivo data demonstrated the association between complement activation (C3b 
deposition) and the glycosylation (WGA staining and SDC-1 expression) of the tumor 
endothelium. Even more indicative for a local complement activation was the discovery of 
neutrophils that began to gain MAC deposition at the interface of the blood vessels (Figure 
6A-B yellow arrows), while neutrophils without physical contact to the endothelium 
remained MAC negative (Figure 6A-B, white arrow). To further prove whether the initiation 
of the complement system on ECs could finally lead to MAC deposition on neutrophils which 
were in direct physical contact with the endothelium, we aimed to mimic our in vivo findings 
by an in vitro approach. To enable the initiation of complement on HUVECs, we sensitized 
the ECs with antibodies directed against CD31. Antibody-labeled HUVECs were then 
exposed to 10% normal human serum (NHS) and non-treated neutrophils. Finally, MAC 
formation was analyzed by immune fluorescence microscopy. Although complement 
activation was intentionally induced on HUVECs, we discovered MAC formation exclusively 
on neutrophils (Figure 6C). This result is further supported by expression analysis of the 
complement regulatory proteins, CD46, CD55, CD59 and factor P in HUVEC, neutrophil and 
several human melanoma cell lines (Figure 6D). CD46 serves as a cofactor for factor I-
mediated proteolysis of C3b/C4b and CD55 accelerates the decay of the C3 convertase
1
. 
CD59 prevents recruitment of C9 to the C5b-8 complex and inhibits the final step of MAC 
formation
1
. Interestingly and in agreement with our assumption that the complement cascade 
is initiated on the endothelium but terminated on neutrophils, HUVECs were found to express 
even 3.5 time higher levels of CD59 than tumor cells, which are known to highly express 
CD59 as indicated by previous studies
21, 42
. Therefore, HUVECs appears to be able to prevent 
MAC deposition on their plasma membrane, whereas low levels of CD46 and CD55 suggest 
vulnerability to the deposition of the early complement factors C3b and the C3 convertase. In 
contrast, neutrophils showed high levels of CD46 and CD55, but only low levels of CD59 
enabling MAC formation. Moreover and in contrast to HUVECs and melanoma cells, 
neutrophils expressed comparable high levels of factor P. This is also in good agreement with 
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the expression of factor P by neutrophils which we found in close proximity to the tumor 
endothelium (Figure 6E).  
Neutrophils are the most abundant circulating leukocytes and recently neutrophils have been 
shown to alter the tumor microenvironment to support tumor progression
55, 56
. Our finding 
that MAC formed on neutrophils in both human and mice tumor tissues suggest that MAC 
positive neutrophils contribute to melanoma metastasis. 
 
Figure 6.  MACs deposit on tumor associated neutrophils but not on EC. 
Cryosections of primary tumors were stained for MAC (green), VWF (white), Ly6g (red) and nuclei 
were stained with DAPI (blue). Representative image of luminal MAC negative neutrophils distant to 
the blood vessel wall (A, white arrow, scale bars=20µm) and MAC positive neutrophils upon contact 
with the endothelium (A, yellow arrows, dotted line reflecting endothelial-luminal interface). The 
MAC intensity on neutrophils in lumen or attached with endothelium was quantified (B). 
Representative microscope image of neutrophils co-cultured with CD31 antibody sensitized HUVECs 
in 10% NHS (C). MAC deposition was detected by immunofluorescence (C, scale bar=20µm). 
HUVECs and neutrophils were distinguished by the shape of their nuclei (HUVEC: oval nucleus; 
neutrophils: polymorphous nucleus). Quantification of fluorescence intensities revealed that MACs 
formed only on neutrophils but not on the endothelial cells (C). Gene expression of complement 
regulatory proteins (CD46, CD55, CD59 and factor P) in human melanoma cell lines (BCL, WM3211, 
WM9, Mel-6, SB-CL-2, MV3, IGR37, BLM, WM4511 and G361), HUVECs and neutrophils suggest 
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that neutrophils are susceptible to MAC deposition (D). Representative image shows that factor P is 
expressed by tumor associated neutrophils (E, scale bars=20µm). Data are shown as the mean ± SD, 
**P< 0.005, ***P< 0.0005. 
 
3.7 MACs on neutrophil leads to ROS production. 
To gain insight into the pathophysiological function of MAC on neutrophil, we adapted the 
aforementioned in vitro model to induce the deposition of MAC on neutrophil. In contrast to 
the experiment with HUVEC, we directly sensitized neutrophils with CD15 antibodies
10
. 
Sensitized neutrophils were treated with either NHS (10%) as a complement source or heat 
inactive serum (HIS) as a control.  FACS analysis confirmed that NHS treated neutrophil can 
lead to the MAC deposition on neutrophil (Figure 7A). For the MAC formation, multiple 
copies of C9 need to interact with C5b-8. After three times washes with PBS, NHS and HIS 
treated neutrophils lysates were collected and measured by western blot. As expected, C9 
deposition was detected in NHS treated neutrophils, but not in HIS treatment control group 
(Figure 7B), confirming the MAC formation in our in vitro model. One of the hallmarks of 
neutrophil activation is the oxidative burst. We asked whether MAC deposition could also 
trigger the neutrophil activation. To answer this question, we measured the release of ROS by 
different techniques. DCFH-DA is a fluorogenic dye that measures intracellular ROS activity. 
After cell uptake, DCFH-DA is deacetylated by cellular esterases and later oxidized by ROS 
into 2’-7’dichlorofluorescein (DCF), which can be detected by FACS or fluorescence 
microscopy. As shown in figure 7C, in comparison to the HIS treated control group, 
neutrophils treated with NHS produced elevated intracellular ROS levels as indicated by the 
increased oxidation of the intracellular fluorescent probe DCFHDA. The corresponding 
quantification revealed almost threefold increased DCF intensity in MAC positive 
neutrophils, compared with that in control neutrophils. These data were further confirmed by 
corresponding flow cytometric experiments. Intracellure oxidant was detected in NHS treated 
neutrophils, but not in control cells (Figure 7E). ROS react with luminol causing the light to 
be emitted, which can be detected with luminescence plate reader. So, the kinetics of the ROS 
generation can be monitored using this luminol-dependent chemiluminescence assay. In our 
study, we also verified that MAC+ neutrophil released increased levels of ROS by this assay 
(Figure 7D). 
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Figure 7. MACs form on neutrophils in vitro and promote ROS production.  
Antibody sensitized neutrophils were treated with 10% NHS or HIS for 30 min and then washed with 
PBS. FACS results show the formation of MAC on NHS treated neutrophils (A). Neutrophil lysate 
were electrophoresed and immunoblotted using anti-C9 antibody. The amount of C9 deposition is 
higher on NHS treated neutrophils, compared with HIS group (B). Intracellular ROS was measured by 
the staining of DCFDA (20 μM, 30 min, scale bar=20µm) (C). Quantification of the microscope based 
detection of the intracellular ROS levels (C). Flow cytometric analysis of MAC mediated intracellular 
ROS production (E). Luminol chemiluminescence was used to monitor the kinetics of the MAC 
induced ROS production (D). Data are shown as the mean ± SD, *P< 0.05, **P< 0.005. 
 
3.8 MAC on neutrophil induces NETs. 
Neutrophil can undergo NETosis, a process of antimicrobial infection and implicate in 
inflammatory disease and tumor progression
65
. Because oxidative stress is a strong promoter 
of NETosis, we next analyzed the effect of MACs on NETs formation. Sensitized neutrophils 
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were treated with NHS, HIS or C5 depleted serum for 3 hours and the respective supernatants 
were collected. ELISA analyses demonstrated a strongly increased concentration of DNA-
Histones fragments in supernatants of NHS treated neutrophils, but not in HIS and C5 
depleted serum treated supernatants (Figure 8A). Citrullination of the histone 3 (CitH3) is 
used as a common marker for NETosis. Accordingly, a robust western blot signal of 
citrullinated Histone3 was detected in MAC+ neutrophil supernatants. In contrast, no CitH3 
was found in the HIS and C5 depleted serum control groups (Figure 8B). 
Immunofluorescence images of NHS treated neutrophils show that externalized DNA 
structures co-localized with the NET-associated CitH3. Neither DNA release nor a positive 
CitH3 staining was detectable in the HIS treated control group (Figure 8C-D). To prove those 
in vitro findings, we then examined the release of CitH3 from MAC positive neutrophils in 
murine (Figure 8E) and human tumor tissues (Figure 8F). In agreement with our in vitro 
results, CitH3 and MAC staining was in close proximity in both human and mouse tissue.  
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Figure 8. MACs promote NETs formation. 
Sensitized neutrophils were treated with 10% NHS for 3 hours to induce NETosis. HIS or C5 depleted 
serum were used as control. ELISA was used to analyze the release of DNA-Histones fragments in the 
supernatants. NHS treated neutrophils released significantly more DNA-Histones fragments,compared 
with control groups (A). Citrullinated Histone3 (CitH3) was detected in NHS treated neutrophil 
supernatant by western blot (B). NHS treated neutrophils and HIS treated control neutrophils were 
stained with an anti-CitH3 antibody and DAPI. Fluorescence microscopy revealed externalized DNA 
structures co-localized with the NETs-associated CitH3 in MAC positive neutrophils but not on 
control neutrophils (C, scale bar=20µm). For quantification, NETs were counted on the whole slide 
and expressed as NETs per view (D). Representative immunofluorescence staining of MACs (green) 
and CitH3 (red) in the cryosections (n=5, scale bars=20µm) of mice melanoma tumor (E) and human 
MM tissues (F) showing the close association between CitH3 and MAC. Bars indicate the mean ± SD, 
*P< 0.05, **P< 0.005. 
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3.9 C5a can not induce MAC formation and neutrophil activation. 
Generated after complement activation, C5a is a potent chemoattractant for pro-inflammatory 
leukocytes and recruits neutrophils to areas of inflammation. As an immune mediator, it plays 
an important role in the initiation and regulation of inflammatory response. Because 
neutrophil activation might not only be related to MAC deposition but also be induced by 
C5a, in further experiments, we analyzed the impact of C5a on neutrophil activation (ROS 
production, NETosis) and MAC formation. Neutrophils were stimulated by recombinant C5a 
(100ng/ml) and FACS was used to measure the changes in neutrophil morphology, ROS 
release and MAC formation. In line with previous studies 
103, 104, 105
 , we found that 
stimulation of neutrophils with C5a promoted cell swelling but failed to induce ROS 
generation and MAC deposition (Figure 4A-C). The C5a induced increase in cell size has 
recently been reported and might represent the reorganization of the cytoskeleton necessary 
for chemotaxis
103
. Also the stimulation of neutrophils with recombinant C5a was not able to 
induce the release of DNA-histone fragments (Figure 9D), suggesting that not C5a 
stimulation but MAC formation is highly relevant for NETosis. 
43 
 
 
Figure 9. C5a is not able to induce neutrophil ROS release, MAC and NETs formation.  
FACS showed that stimulation of neutrophils with recombinant C5a (100ng/ml) induced cell swelling 
(A) but failed to induce ROS generation (B). C5a (100ng/ml) stimulated neutrophils were further 
treated with 10% NHS for 30 min to induce MAC formation on neutrophils, 10% HIS was used as a 
control. MAC formation was measured by FACS and quantification indicates the failure of MAC 
formation upon stimulation with C5a (C). C5a stimulation was neither able to induce the release of 
DNA-Histone fragments in the HIS nor the NHS treatment group. As a positive control, CD15 
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antibody primed neutrophils released significantly increased levels of DNA-Histones fragments after 
incubation with NHS (D). Bars indicate the mean ± SD, *P< 0.05, **P< 0.005. 
 
3.10 Neutrophils in close proximity to the tumor blood vessel wall. 
Although C5a stimulation was not potent to induce ROS production or NETosis in 
neutrophils, the presence of C5a around the tumor vasculature (Figure 3D-E) and the 
complement activation fragments deposition on the vessel wall (Figure 3A-B) suggest that 
neutrophils might be recruited around the tumor vessel. We hypothesized that neutrophils 
recruited around tumor vessel mediate EC dysfunction. To this end, we first checked the 
distribution of neutrophils in mice and human melanoma.  Human and mouse cryosections 
were stained for neutrophil and VWF. In human tissue, CD15 was used as a marker for 
neutrophil, while Ly6g was used as mouse neutrophil marker. Within the tumor, numerous 
neutrophils marginated along or penetrated the wall of blood vessels in both human (Figure 
10A) and mouse tumor tissue (Figure 10B), which is also conform with the C5a induced cell 
swelling (Figure 9A).  
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Figure 10. Neutrophils marginate along or penetrate the blood vessel walls in human and mice 
tumor.  
Cryosections of mice and human malignant melanoma tissue were analyzed by immunofluorescence 
staining for the distribution of neutrophils. Nuclei were stained with DAPI. VWF antibody was used 
to identify tumor vessel. Ly6g antibody was used to stain mouse neutrophil (A) and human neutrophil 
was stained with CD15 antibody (B). Within the tumor, numerous neutrophils marginate along or 
penetrate the wall of vessel (A-B, n=5, scale bar=20µm). 
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3.11 MAC-activated neutrophils contribute to endothelial barrier disruption in vitro. 
We have shown that MAC on neutrophil mediated neutrophil ROS release and NETs 
formation (Figure 7-8). ROS as well as NETs could potentially be toxic for ECs
59, 64, 69
. 
Therefore, we postulated that in close contact with EC, MACs activated neutrophils could 
induce the dysfunction of ECs. To study neutrophil-EC crosstalk, we co-cultured HUVEC 
with NHS treated neutrophils in vitro. As shown in Figure 11A, MAC positive neutrophils 
induced gap formation in a confluent EC monolayer. The mean level of relative gap areas in 
co-culture with MAC+ neutrophils was almost twofold increased compared with control 
group (Figure 11A). Electric Cell-substrate Impedance Sensing (ECIS) is a real time 
impedance based method to study the barrier function of ECs. The trans-endothelial electrical 
resistance (TEER) of a ECs monolayer can be measured by ECIS. ECs at confluence exhibit 
a high TEER, reflecting the integrity of the EC monolayers. When the permeability of the 
monolayer is disrupted, the electrical resistance will dramatically decrease. Data from ECIS 
experiments further confirmed that co-culture with MAC positive neutrophils decreased the 
TEER of an endothelial monolayer suggesting an increased vascular permeability (Figure 
11B).  
To further prove the NETs formation is the cause of the disrupted vascular barrier, we 
performed additional ECIS experiments with the treatment of NETosis inhibitors. Blockage 
of NETosis by the protein arginine deiminase 4 (PAD4) inhibitor CI-amidine prevented the 
neutrophil induced breakdown of the endothelial resistance (Figure 11C). Also the treatment 
with DNAse was able to slightly counteract the endothelial destructive effect of the NETs. 
However the effect was statistically not significant indicating that histones or other NETs 
related cytotoxic factors remained unaffected by DNAse treatment (Figure 11C).  
 
 
 
 
 
47 
 
Figure 11. Activated neutrophils provoke EC dysfunction.  
Integrity of a HUVEC layer after 6 hours of treatment with MAC positive neutrophils or control 
neutrophils was analyzed by immunofluorescence staining of CD31 and DAPI (A, scale bar=50µm). 
HUVECs and neutrophils were distinguished by the shape of their DAPI stained nuclei (HUVEC: 
oval nucleus; neutrophils: polymorphous nucleus). Gap areas in the HUVEC monolayer were 
measured and corresponding quantifications show increased relative gap areas after co-culture with 
MAC positive neutrophils (A). Permeability of HUVEC was determined using Electric Cell-substrate 
impedance sensing (ECIS). Co-culture with MAC neutrophils (1×10
5
 per electrodes) decreased the 
impedance of the endothelial monolayer, indicating an increased vascular permeability (B). The 
PAD4 inhibitor CI-amidine (50µM) prevented the MAC neutrophil induced breakdown of the 
endothelial resistance. Treatment with DNAse (100U/ml) was less effective (C). Bars indicate the 
mean ± SD, *P< 0.05, **P< 0.005. 
 
3.12 Perivascular neutrophils increase the endothelium permeability in tumor tissue. 
We intended to measure this supposed permeability increase across the endothelial barrier 
also in our tumor tissue sections. For this purpose, we analyzed the leakage of IgG from the 
blood vessel into the adjacent tissue by immune fluorescence analysis. Normally endothelial 
monolayers are quiescent and vascular endothelium stabilization keeps the regular blood flow 
and provide barrier to plasma and cell extravasation. The leakage of IgG from the blood 
vessel can be used as a marker for disrupted endothelial barrier. To this end, tumor 
cryosections were stained for Ly6g, VWF, anti-mouse IgG and DAPI. In the absence of 
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perivascular neutrophils, IgG located only along the blood vessel wall (Figure 12A, 
arrowheads); however, IgG were found in the tissue beyond the blood vessel in neutrophil 
rich region (Figure 12A arrows). Quantitative analysis revealed significant more IgG leakage 
from vessels disrupted by neutrophil accumulation (Figure 12B). This suggests that 
neutrophils in the vicinity of the blood vessels disrupt the ECs monolayer barrier and increase 
the permeability. To better attribute the increased leakage of the endothelial barrier to 
neutrophil activation we treated tumor-bearing mice with the PAD4 inhibitor CI-amidine. We 
cannot exclude that the impairment of the neutrophil activation through PAD4 inhibition. 
Therefore, to allow a reliable quantification, we compared the IgG leakage in vessels with or 
without neutrophils. The results show that impaired neutrophil activation (Figure 12C-D) 
abolished the ability of the neutrophils to compromise the endothelial barrier. 
 
 
Figure 12. IgG leakage from the blood vessel into the adjacent tissue by immune fluorescence 
analysis. 
For the in vivo proof of our findings, immunofluorescence staining of Ly6g (white), VWF (green) and 
IgG (red) in cryosections of mouse primary tumors were performed to measure the blood vessel 
integrity in vivo (A, scale bar=20µm). Nuclei were stained with DAPI (blue). In the absence of 
perivascular neutrophils, IgG locates only along the blood vessel wall (arrowheads). In neutrophil rich 
regions, IgG leaks out into the tissue and was detected beyond the blood vessel border (arrows, A). 
IgG leakage areas to the vessel perimeter ratio were quantified. Vessels with perivascular 
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accumulation of neutrophils exhibit a higher ratio compared with the vessels without neutrophils 
recruitment (B). Immunofluorescence staining of Ly6g (white), VWF (red) and IgG (green) in 
cryosections of CI-amidine (10mg/kg, n=5) treated mouse tumors were performed to measure the 
blood vessel integrity (C). Quantitative analysis revealed no significant difference of IgG leakage 
between vessels with or without neutrophils (D). Scale bars = 20µm. Bars indicate the mean ± SD, 
*P< 0.05. 
 
3.13 Disruption of the MAC formation protects the vascular integrity. 
The tight physical contact between the MAC-activated neutrophils and the tumor 
endothelium induced the disruption of the tumor blood vessel barrier. To confirm these 
findings at the functional level, the relevance of the complement system for endothelial 
barrier disruption was tested in C5
-/-
 mice. In mouse models of cancer, complement 
deficiencies (C3, C4 or C5aR) and treatment with complement inhibitors have been 
associated with impaired tumor growth and suppressed metastasis
23, 24, 32, 33
, whereas C5 
deficiency did not affect the growth of the primary tumor
37
. Our experiments with C5-/- mice 
confirmed these results (Figure 13A-B). In addition, the recruitment of neutrophils due to a 
lack of C5a in the C5
-/-
 mice affected the total amount of neutrophils within the tumors tissue 
(Figure 13D). Therefore, to allow a reliable quantification, we compared the IgG leakage in 
vessels with or without neutrophils in tumor tissues of C5
-/-
 mice. The results show that the 
disruption of the complement cascade (Figure13C) abolished the ability of the neutrophils to 
compromise the endothelial barrier. To prove whether an impaired endothelial barrier may 
promote tumor cell extravasation we measured the transmigration of human melanoma cells 
by transwell assays. In line with an increased vascular permeability, the number of 
transmigrated melanoma cells through an endothelial monolayer was almost twofold 
increased in the presence of MAC positive neutrophils (Figure 13E). To further investigate 
the impact of complement activation and MAC formation in melanoma metastasis, we 
performed a group of lung metastasis experiments by intravenous injection of melanoma into 
WT and C5 deficient mice. As shown in the figure 13F, we detected less lung metastasis in 
C5 deficient mice. Taken together, our data indicate that perivascular MAC positive 
neutrophils increase the EC barrier permeability, promoting tumor cells transmigration in 
vitro. 
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Figure 13. Effect of C5 deficiency on tumor growth and metastasis.  
Wild type mice (n=5) and C5
-/-
 mice (n=5) received an intradermal injection of 7.5×10
5
 ret transgenic 
melanoma cells. After 15 days, mice were sacrificed and tumors weight and volume were measured. 
C5 deficiency did not affect the primary tumor growth (A-B). Immunofluorescence staining of Ly6g 
(white), VWF (green) and IgG (red) in cryosections of C5 deficient mouse tumors were performed to 
measure the blood vessel integrity (C, scale bar=20µm). The IgG leakage in vessels with or without 
neutrophils was quantified and not obvious IgG leakage was observed around vessel with neutrophils 
(C). Compared with wild type mice, the total amount of neutrophils was decreased but not 
significantly in C5 deficient mice (D). Transmigration of the human melanoma cells MV3 through 
confluent HUVEC layers co-cultured for 6 h prior to the tumor cell challenge with MAC positive 
neutrophils or HIS treated control neutrophils (E). 5×10
5
 B16F10 melanoma cells in 100 µl PBS were 
intravenously injected into the tail veins of wild type mice (n=5) and C5
-/-
 mice (n=5) to induce lung 
metastases. Lung metastasis was decreased in C5 deficiency mice (F). Bars indicate the mean ± SD, 
NS: not significant, *P< 0.05. 
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3.14 Undetectable complement activation and less MAC-neutrophils in human non-
metastatic skin tumors. 
The crosstalk between complement and neutrophil affects the permeability of tumor blood 
vessels, which further potentially impact the tumor metastasis. To further confirm the 
pathophysiological relevance of this crosstalk for metastasis in humans, we compared four 
different types of human skin tumors. The selected tumor entities differ in their potential to 
metastasize. Malignant melanomas are highly metastatic skin cancer. Human basal cell 
carcinoma (BCC) and keratoacanthoma (KA) are two rarely metastasizing, semi-malignant 
skin tumors. Nevocytic nevi (NCN) are non-metastatic, benign skin tumors. We compared 
the complement activation status (C3b/iC3b deposition at the blood vessel wall, Figure 14A) 
and the presence of MAC-neutrophils (Figure 14B). Highly conform to the metastatic 
property of those four human skin tumors, we detected a very limited number of C3b/iC3b 
deposited in vessels (<5%) of BCC, KA and NCN tissues; in contrast 12% of melanoma 
vessels are positive for C3b/iC3b staining (Figure 14A). In comparison to 52% MAC positive 
neutrophils in melanoma, we also found less MAC positive neutrophils in BCC (16%) and 
KA (12%). No MAC-neutrophils were detectable in NCN (Figure 14B). These results 
indicate a positive correlation between complement activation and the ability of human skin 
tumors to metastasize. 
 
Figure 14. complement activation status in human skin cancers.   
Human basal cell carcinoma (BCC, n=6), keratoacanthoma (KA, n=5) and Nevocytic nevi (NCN, n=5) 
tissue samples were stained for VWF and C3 cleavage products (C3b/ iC3b) (A) or CD15 and MAC 
(B). Nuclei were stained with DAPI. Quantification showed a very limited number of C3b/iC3b 
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deposited in vessels (<5%) of BCC, KA and NCN tissues in comparison to melanoma (A). In addition, 
less MAC positive neutrophils were detected in BCC (16%), KA (12%) and non-detectable MAC-
neutrophils in NCN compared to 52% MAC positive neutrophils in melanoma (B). Bars indicate the 
mean ± SD, *P< 0.05, **P< 0.005. 
 
3.15 LMWH blocks complement activation in vitro. 
The observed correlation between the glycocalyx related C3b deposition (Figure 5B-C) 
followed by the recruitment and activation of neutrophils and the disruption of the tumor 
vasculature(Figure 10-12), prompted us to assess whether LMWHs are able to prevent tumor 
related complement activation. Heparins are strongly related to the naturally occurring 
heparin sulfate, a major component of the endothelial glycocalyx. Zaferani et al.
45
 showed 
that various complement factors have heparin binding sites enabling their storage within the 
endothelial glycocalyx and thus their deposition at the blood vessel wall. To better understand 
the anti-metastatic properties of heparins and the impact of heparin on tumor-associated 
complement activation, we performed further in vitro and in vivo experiments.  
In the first set of experiment, we compared the two LMWHs, tinzaparin and N-acetylheparin 
(NAH, a heparin without anticoagulant properties). The complement inhibitory activity of 
both LMWHs was assessed by analyzing the haemolytic activity of the classical pathway 
(CH50) and the alternative pathway (APH50). The CH50 assay tests the total hemolytic 
activity of the classical and terminal pathways, which depends upon lysis of sheep red blood 
cells pre-coated with rabbit anti-sheep red blood cell antibody by human serum. Similarly 
with the CH50 assay, the APH50 assay measures the total alternative pathway hemolytic 
activity to lyse unsensitized chicken erythrocytes by human serum. Both CH50 and APH50 
assay results were showed in reference to a pool of normal human serum as standard (100%). 
Treatment with tinzaparin significantly blocked the classical (Figure 15A) and the alternative 
(Figure 15B) complement pathway by 80% and 95% respectively. NAH were also able to 
decrease the CH50 and APH50 values; however tinzaparin was significantly more efficient 
than NAH (Figure 15A-B). In the next set of experiments, we analyzed whether treatment 
with tinzaparin could also inhibit MACs formation on neutrophils. Sensitized neutrophils 
were treated with NHS, HIS or NHS with the supplement of tinzaparin (100IU/ml) for 30 
min. Anti-human MAC-FITC antibody and anti-human citrullinated histone H3 antibody 
were used for the MACs and NETs immunofluorescence staining. As shown in Figure 15C, 
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MACs presented on NHS treated neutrophils whereas administration of tinzaparin was 
sufficient to completely inhibit MACs formation. Quantification also revealed a significant 
reduction of the intensity of MAC on neutrophils for tinzaparin treatment. 
 
Figure 15.Tinzaparin inhibits complement activation in vitro.  
Haemolytic complement function of the classical pathway (CH50) and the alternative pathway 
(APH50) was significantly reduced by the LMWH tinzaparin and NAH. Tinzaparin was more 
efficient than NAH (A-B). Representative immunofluorescence images of antibody sensitized 
neutrophils treated with 10% NHS or with 10% NHS supplemented with tinzaparin (100IU/mL). The 
speckled MAC staining on NHS treated neutrophils was significantly abolished by tinzaparin (C, 
scale bar=20µm). Bars indicate the mean ± SD, *P< 0.05, **P< 0.005, ***P< 0.0005. 
 
3.16 Tinzaparin blocks MAC-related neutrophil activation in vitro. 
We have shown that MAC is a potent activator of neutrophil activation, resulting in oxidative 
burst and formation of NETosis. We next analyzed the impact of tinzaparin treatment on 
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MAC-induced neutrophil activation. As show in Figure 16A, compared with NHS treated 
neutrophils group, DNA-histone fragments were significantly reduced in the supernatant of 
tinzaparin-NHS treated neutrophils. Western blot results further proved that tinzaparin could 
significantly prevent the release of CitH3 into the supernatant (Figure 16B). In comparison to 
the NAH, tinzaparin was again more efficient to block NETosis (Figure 16A-B) suggesting 
that tinzaparin was more applicable for further experiments. The effect of tinzaparin on ROS 
production was measured by chemiluminescence assay. Compared with the NHS group, 
tinzaparin treatment reduced the MACs induced ROS release from neutrophils (Figure 16C). 
As MAC positive neutrophils reduce the endothelial barrier function, we checked whether 
tinzaparin was sufficient to protect the endothelium. ECIS measurement showed that 
tinzaparin effectively prevented MAC induced break down of the electrical resistance (Figure 
16D). Taken together, our in vitro results indicate that tinzaparin significantly inhibited 
MACs formation and prevented ROS release, NETs formation and thereby attenuated MAC 
activated neutrophil mediated EC dysfunction.  
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Figure 16. Tinzaparin treatment blocks ROS release and Netosis formation in vitro. 
To analyze the tinzaparin treatment effect for neutrophils activation, we detected the NETs formation 
and ROS release. Tinzaparin was more efficient than NAH to block NETosis in NHS-treated 
neutrophils as indicated by the significantly reduced release of DNA-histone fragments (Tinzaparin, 8 
µM; NAH, 8 µM) (A) and citrullinated histone3 (B). Luminol chemiluminescence assay shows a 
reduction of MAC-induced ROS release in the presence of tinzaparin (C). TEER measurement reveals 
that supplementation of NHS with tinzaparin (100IU/mL) counteracts the NHS induced ECs 
dysfunction (D). Bars indicate the mean ± SD, *P< 0.05, **P< 0.005, ***P< 0.0005. 
 
3.17 Tinzaparin block complement activation in vivo. 
We selected tinzaparin also for our following in vivo experiments because this LMWH has 
frequently been demonstrated to possess anti-complement effects
45, 46, 52
. In addition, our own 
previous work showed that the treatment with tinzaparin attenuated tumor progression and 
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metastatic burden in murine animal models
93, 94
. To prove of our findings in vivo, we treated 
ret tumor engrafted mice with tinzaparin. The complement activtion status in tinzaparin 
treated primary tumor were measured by immunofluorescence. Daily intradermal 
administration of tinzaparin to ret tumor engrafted mice prevented the deposition of the C3 
fragment C3b/iC3b at tumor blood vessel walls (Figure 17A-B). In agreement with our in 
vitro experiments, MAC formed on neutrophils in primary control tumor; however, blocking 
complement activation by tinzaparin decreased MACs formation on tumor neutrophils 
(Figure 17C). Quantification also revealed a significant reduction of MAC intensity by 75% 
in tinzaparin treated tumors, compared with non-treated tumors (Figure 17D). Taken together, 
these results confirmed the complement inhibition effect by LMWH in vivo. A schematic 
model of current study is present in Figure 18. 
 
Figure 17. Tinzaparin blocks complement activation in primary tumor.  
Tumor bearing mice were treated with vehicle or tinzaparin and cryosections of primary tumors were 
analyzed by immunofluorescence staining (n=5, scale bar=20µm). Tinzaparin treatment reduced the 
deposition of C3fragments along the vessel wall compared with control tumors (A). Quantification 
revealed a significant reduction of C3 fragments deposition after tinzaparin treatment (B). MAC 
positive neutrophils are showed in the in tumors of control mice. In contrast, treatment with tinzaparin 
results in a decreased MAC formation on neutrophils (C). Quantification showed a significant 
reduction of MAC intensity on neutrophils after tinzaparin treatment (D). Data are shown as mean ± 
SD, *P< 0.05, **P< 0.005.  
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Figure 18. Schematic model of current study. 
The schematic overview shows the crosstalk between the complement system, neutrophils and ECs in 
the tumor microenvironment (A-B). Complement activation at the endothelial-blood interface leads to 
the C5a mediated recruitment of neutrophils. Upon contact with the endothelium, MACs are formed 
on neutrophils, which mediate neutrophil activation represented by ROS release and NETs formation. 
Complement activated neutrophils increase the permeability of the endothelium allowing the 
transmigration of melanoma cells. Treatment with tinzaparin can block complement activation and 
thus tumor cell transmigration. 
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4 Discussion 
The complement system is a major effector of the innate immunity and its role in pathogen 
defense has been extensively studied
1, 4
. High capacity of metastases is the malignant 
melanoma´s main characteristics and several complement effectors (such as C3a, C5a) 
contribute to melanoma progression
91, 92
. In the frame of the complement activation, 
neutrophils are recruited to the inflamed site and manipulated by the primary tumor to 
participate in various steps of the metastatic cascade
55, 56, 77
. The aim of our study was to 
investigate the involvement and crosstalk between complement, neutrophils and the tumor 
endothelium in the melanoma microenvironment. 
To study the role of complement in malignant melanoma, we analyzed tumor biopsies of 
melanoma patients, we applied murine melanoma models and we used several in vitro 
experiments. In summary, we showed that tumoral ECs recruit complement factors from the 
blood to their surface to provide a platform for the initiation of the complement cascade, 
especially the lectin pathway activation. The associated production of the complement C3 
fragments and C5a correlated with neutrophil attraction. In close proximity to the blood 
vessel wall, these recruited neutrophils are further activated by the complement-derived 
MAC. Profound neutrophil activation, characterized by an oxidative burst and the NETs 
formation, therefore increased the permeability of the tumor endothelium which in turn 
enables extravasation of tumor cells. We were able to block this effect by chemical inhibition 
of the MAC, and likewise the metastatic spread of melanoma cells was prevented in C5 
deficient mice, which were unable to form MAC. MAC deposition on tumor-associated 
neutrophils was also found in human melanomas but not in rarely metastasizing basal cell 
carcinomas or non-metastatic keratoacanthoma and nevocytic nevi. Interestingly, 
administration of the LMWH tinzaparin to melanoma bearing mice prevented complement 
associated neutrophil activation and stabilized the vascular barrier explaining the efficient 
blockage of tumor cell metastasis. 
The complement system and its crosstalk with the cells of innate and adaptive immune 
responses is an emerging field of research in life sciences, as evidenced by several recent 
articles in high-impact journals
22, 42, 106
. Our work describes the first functional analysis of the 
MAC and its impact on neutrophil activation during the progression of melanoma (Figure 
18). Moreover, our results provide a sound explanation of a triangular molecular crosstalk 
59 
wherein the imbalanced complement activation in tumors promotes neutrophil activation 
followed by endothelial dysfunction and thus increased metastasis. 
 
4.1 Complement activation in melanoma microenvironment 
A growing body of data show that imbalanced complement activation in the tumor 
microenvironment participates in chronic inflammation and suppressive immune responses
23, 
32
. In addition, clinical data demonstrated complement activation in cancer patients. Levels of 
complement effectors such as C3a, C5a, C3 and MBL in patients’ plasma/serum sample or 
tumor tissues positively correlate with promoted tumor growth and poor outcome in patients 
suffering from lung cancer
38, 107
, ovarian cancer
39
, colorectal cancer
40
 and chronic lymphatic 
leukemia
108
.  
Melanoma is one of the most aggressive forms of skin cancer and exposure to sun or ultra 
violet (UV) radiation has been accounted for the major cause of melanoma
109, 110
. UV 
radiation contributes to the DNA damage and leads to immunosuppression, which is a major 
risk factor for melanoma development
109
. Previous reports showed that C3 fragments C3b 
and C3d were deposited on epidermal cells after the exposure of the skin to UVB
111
. 
Moreover, UVA is a potent oxidizer of cellular molecules, and complement can be triggered 
in to action by UVA-altered cell lipids and other cell structure
112
. Accordingly, recent 
evidence indicated that radiation induced tumor cell damage could induce transient 
complement activation and up regulate the release of C3a and C5a, subsequently leading to 
DC and CD8 anti-tumor response
28
. Based on these observations, we postulate that melanoma 
progression is associated with complement activation.  
C3 plays a key role in the classical and alternative pathways of the complement system. In 
non-small cell lung cancer, low C3 level is related to shorter overall survival and disease-free 
survival rates
38
. Apart from cancer, anti-neutrophil cytoplasmic antibody associated vasculitis 
(AAV) is a group of autoimmune disease and complement activation is crucial for the 
development of AAV. Accumulating evidence has shown that low serum C3 level at 
diagnosis was associated with severity and poor out-comes of AAV
113
. In this study, ELISA 
results show decreased C3 level in stage IV melanoma patients’ plasma (Figure 1A). Several 
studies suggested the use of complement as biomarkers for cancer diagnosis and prognosis. 
Increased levels of C3 fragments (e.g. C3b/C3c and C3f) have been detected in serum of a 
60 
variety of cancer patients
21
, including breast cancer, pancreatic cancer, leukaemia and 
lymphoma. Moreover, C3a and C5a are potent proinflammatory mediators. Increased levels 
of C3a have been reported in the serum of patients with lymphoma, oesophageal cancer and 
colorectal cancer
21
. At higher concentration, C5a recruits MDSCs into tumor and exert 
immunosuppressive effects by ablating CD8 T cell response
32
. C5a could also stimulate 
angiogenesis and promote cancer cell invasion and migration
22, 91
. Inhibition of the binding of 
C5a to its receptors was demonstrated to be associated with a decreased tumor growth in 
experimental mouse models
91, 114
. In the present study, we show that the complement 
effectors C3b, C3a and C5a are elevated in human melanoma blood samples, indicating 
systemic complement activation in melanoma patients (Figure 1B-D). Thus, the 
determination of complement related proteins may be potentially useful in the melanoma 
screening and tumor staging. 
To support our ELISA data, we evaluated the presence of complement effectors in 
cryosections of human and mice malignant melanoma tissue. In our study, C3 cleavage 
products deposit along the tumor vasculature in both human and mice tumor tissues, 
indicating that activation of complement proteins occur at the blood vessel interface (Figure 
2A and 3A). In agreement to a previous study, we detected no complement activation in 
murine melanomas at an early stage (Figure 3C) but only in advanced tumors suggesting a 
stage-dependent complement-promoting environment. The work by Marks et al.
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 reported 
that enforced deposition of complement factors at EC is a potent and rapid stimulus for 
neutrophil-endothelial adhesion. The binding of neutrophils to the vascular endothelium is an 
early event in their recruitment into acute inflammatory lesions. In strong accordance with the 
notion of tumor blood vessel restricted complement activation, we also detected high levels 
of C5a in close proximity to blood vessels (Figure 3D). C5a is a potent chemoattractant for 
pro-inflammatory leukocytes and recruits neutrophils to areas of inflammation and tissue 
damage
1
 (Figure 3F). Thus, the enrichment of complement effector C3 fragments and C5a 
along the vasculature is a sound explanation for the observed recruitment of neutrophils 
around tumor vessels (Figure 10). However, C5a is not able to induce ROS formation and 
NETosis by its own (Figure 9) further emphasizing the potential relevance of MAC as a 
potent physiological activator of neutrophils. Additionally, we found no evidence of C3b 
deposition on the vasculature of the lung, liver and kidney of tumor bearing animals (Figure 
4), indicating the complement activation is specific in the tumor microenvironment. 
Accordingly, MAC deposition was not found on tumor-associated macrophages, dendritic 
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cells or T cells, or on the neutrophils of peripheral organs, suggesting MAC forms only on 
tumor associated neutrophils. 
To better understand the initiation of the complement cascade in our animal model, we 
quantify the accumulation of early complement components (Figure 5A; C1q, C4, MBL and 
Factor B). Our experiments suggest the predominant involvement of the lectin pathway. 
However, the tight molecular interconnection of the complement system does not exclude the 
contribution of the other activation routes. For instance, previous studies suggested that 
coagulation and fibrinolytic cascade related proteases such as thrombin and plasmin are able 
to trigger complement activation through the direct cleavage of C5
22
. In the earlier study, we 
showed that melanoma cells are able to induce coagulation through the formation of thrombin 
via tissue factor or through the release of VEGF
115, 116
. In the present study we also 
investigated the potential crosstalk between coagulation and the complement; however we 
were not able to found a significant correlation between blood vessel occlusion and 
complement activation suggesting that in the melanoma microenvironment hypercoagulation 
is less relevant for complement activation. 
MBL deposition and the presence of C3 cleavage products along the tumor vasculature, 
suggest that activation of complement proteins occurred at the blood vessel interface in a 
subset of tumor blood vessels. The MBL can recognize ECs with an aberrant glycosylation at 
their surface
102
 and evidence for the activation of lectin pathway has been reported in patients 
suffering from colorectal
117
 and ovarian cancer
39
. In this study we discovered that the degree 
of C3b/iC3b deposition was related to the endothelial glycosylation and the surface 
expression of SDC1suggesting that tumor ECs exhibit a disease-related phenotypes (Figure 
5B-C). Interestingly, the expression of endothelial SDC1 (a highly glycosylated 
proteoglycan) has previously been linked to enhanced complement activation
51
. So, the 
altered expression of SDC1 and the changed glycosylation of the surface structures may 
explain the prevailed involvement of the lectin pathway 
118, 119, 120, 121
.This is also supported 
by the recent findings from Talsma et.al documenting that a modified heparan sulfate 
synthesis in ECs is associated with an increased deposition of the MBL
102
 . However, more 
details about altered surface structures of tumor ECs and the crosstalk between the 
glycosylation and complement activation should be further explored.  
In addition, SDC1 is involved in several physiological processes such as angiogenesis
122
. 
Removal of SDC1 from the endothelial surface is a common marker for endothelial cell 
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damage 
123, 124
. In this study, we found a positive correlation between SDC1 expression and 
C3b/iC3b deposition indicating that the initiation of the complement is not triggered by 
damaged ECs but dependent on an intact endothelium. 
 
4.2 MAC formed on neutrophils but not on EC 
Classical, alternative and lectin pathways converge on a common terminal pathway: the 
formation of the MAC. To investigate the distinguish role of complement in melanoma 
environment, we further analyzed the presence and localization of this terminal complex in 
the tumor tissue by immunofluorescence staining. We have already found C3 fragments 
deposit around tumor vasculature, so we hypothesized the deposition of MAC along the 
tumor vessel. To our surprise, we could not detect significant levels of MAC at the 
endothelium; however, we discovered that about 60% of all tumor-related neutrophils were 
MAC positive in both human and mice primary tumor tissue (Figure 2C and 3G). 
One of the main functions of complement system is to directly kill invading pathogens 
through the formation of MAC. In principle, deposition of critical amounts of MACs disrupts 
the bilayer of the cell membranes, leading to cell lysis. However, most nucleated cells, 
including neutrophil, have several protection mechanisms to counteract complement-
mediated cellular lysis. For example, through a combination of ion pumps, complement 
regulators (CD59) and active recovery processes (endocytosis), most nucleated cells actively 
remove the MAC 
5, 10, 16
. Neutrophils can also protect themselves against lytic killing by 
transient cell swelling and metabolic depletion
5, 10
. At sublytic levels, MAC deposition 
permits Ca
2+
 influx and interacts with other signaling molecules involving G-protein-coupled 
receptors and NF-κB
5, 15, 16, 125
. MACs are able to induce many different effects that have 
been associated with altered cell proliferation, induction or inhibition of apoptosis and 
inflammasome activation in various cell types, for example, macrophage, microglia, 
epithelial cell and some tumor cells
5, 16, 125
 . 
In this study, we further analyzed the localization of MAC negative and MAC positive 
neutrophils within the tumor vasculature. We observed that in mice tumor tissues most of 
non-attached luminal neutrophils remained MAC negative, whereas neutrophils attached to 
the tumor endothelium gain the MAC complex (Figure 6A-B). This result suggests that the 
deposition of the MAC assembly on the neutrophils occurs at surface of the blood vessel wall 
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during neutrophils recruitment and transmigration from the blood through the endothelium 
into the tumor tissue.  
To test whether the initiation of the complement system on ECs could finally lead to MAC 
deposition on adjacent neutrophils, we intentionally induced the complement activation on 
HUVECs prior to the co-culture with neutrophils. MAC in vitro staining shows that MACs 
exclusively form on neutrophils but not on HUVEC (Figure 6C), indicating MAC is de novo 
formed on neutrophils but not transferred from EC surface. Moreover, Morgan et al. reported 
that neutrophils can remove MAC by endocytosis
126
. Our staining result also shows that 
MAC can be detected both on the neutrophil surface and in the cytoplasm. To further 
understand the mechanism of MAC formation exclusively on neutrophils, we next analyzed 
the expression of the complement regulatory proteins CD46, CD55, CD59 and factor P in 
HUVEC, neutrophil and several human melanoma cell lines (Figure 6D). Our data reveals 
that in contrast to CD59, neutrophils strongly express factor P. Factor P can recruit the 
C3(H2O) and C3b to the cell surface and serves as the platform for alternative pathway 
activation
1
. Furthermore, Factor P can also stabilize the C3 convertase and bind on the 
pathogens or activated cells surface to promote the complement activation. Neutrophils can 
further amplify the complement cascade e.g. by the release of factor P which lead to a 
positive feedback loop of neutrophil activation
72
. Our results also show that neutrophils are 
almost the only cells expressing factor P, suggesting neutrophils tend to mediate complement 
related disease (Figure 6E). Expressed on most of nucleated cell, CD59 is the most important 
negative regulator of the MAC formation. CD46 acts as a cofactor for the inactivation of C3b 
and C4b. CD55 dissociates the C3 convertase. Therefore, CD46 and CD55 are not able to 
inhibit MAC formation directly. In agreement with our assumption that the complement 
cascade is initiated on the endothelium but terminated on neutrophil, weak expression of 
CD59 by neutrophils (Figure 6D) suggests that they could not sufficiently prevent the 
formation of the MAC. In contrast to neutrophils, ECs express high levels of CD59 
suggesting their protection against MAC formation whereas low levels of CD46 and CD55 
may promote the deposition of early complement factors.  
 
4.3 MAC on neutrophil lead to ROS production and NETs 
To gain further insights into the pathophysiological function of MAC on neutrophil, we 
induced the MAC formation on neutrophils in vitro and further confirmed the MAC 
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formation by FACS and western blot (Figure 7A-B). One of the hallmarks of neutrophil 
activation is the oxidative burst, so, we first checked the ROS release from MAC positive 
neutrophils. We measured the release of ROS by different techniques, including DCF 
fluorescence staining, FACS and chemiluminescence assay. Using these methods, we 
confirmed that MAC on neutrophils leads to ROS production (Figure 7C-E). ROS can 
mediate antimicrobial activity and participate in stress signaling in cells. Moreover, ROS 
cause cell death and are associated with tissue damage. For example, ROS initiated Ca
2+
 
signaling plays an important role in regulating endothelial barrier function
85
. Interestingly, 
neutrophil-derived ROS have been reported to directly activate the complement in fluid 
phase
127 
. 
Oxidative stress is a strong promoter of NETosis
128
, which involves the secreted nuclear 
chromatin and the release of granule proteins. We therefore further investigated MAC 
induced NETs formation (Figure 8). Histone citrullination is a decisive event during NETosis 
and thus used as molecular marker.  As expected, a robust western blot signal of citrullinated 
Histone3 (CitH3) and the release of DNA-histone fragments were detected in MAC+ 
neutrophil supernatants. We can also find the externalized DNA structures co-localized with 
the NETs-associated CitH3 in NHS treated neutrophils.  For the in vivo proof of our findings, 
we evaluated cryosections of tumor tissues for the MAC associated CitH3 staining. In 
agreement with our in vitro results, CitH3 and MAC staining were in close proximity in both 
human and mouse primary tumor tissues. Notably, NETs can activate the alternative 
complement pathway
129
 and NETs may influence different steps of the tumor development, 
including tumor growth, metastasis and cancer associated thrombosis
65, 67, 130
. 
Taken together, our results show that in human and murine melanoma tissue the complement 
system is activated at the endothelial-blood interface. Complement effector molecules C3 
fragment and C5a are produced and neutrophils are thereby recruited and activated. The 
terminal formation of MAC at the neutrophils surface drives further neutrophil activation 
characterized by ROS production and release of NETs. 
 
4.4 Perivascular activated neutrophils contribute to endothelial barrier disruption 
Neutrophils are the most abundant immune cells in human immune system and many 
proinflammatory factors contribute to the recruitment of neutrophils to the inflammatory 
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sites. Our study indicates an imbalanced complement system resulting in MAC formation in 
the tumor microenvironment. In the course of the complement cascade chemoattractant C5a 
is formed and deposited around tumor vessels suggesting neutrophil recruitment to the tumor 
blood vessel. Neutrophils have varied functions in the tumor microenvironment and 
increasing body of evidence suggests that neutrophils are educated by primary tumors in 
order to support the formation of metastasis in distant organs
58
. Tumor metastasis depends on 
in increased permeability of the endothelium. Therefore, we hypothesize that imbalanced 
complement cascade mechanistically links neutrophil activation with dysfunction of 
endothelium and subsequent melanoma cells extravasation.  
In human and mice tumor tissues, numerous neutrophils marginated along or penetrated into 
the wall of tumor blood vessels (Figure 10). Because MAC deposition on neutrophils 
promotes an oxidative burst (Figure 7) and induces NETosis (Figure 8), these neutrophils can 
locally induce or amplify the permeability of the endothelium
131
. For example, ROS interact 
with ECs and increase the intracellular oxidative stress, which may provoke cellular damage 
and transformation
64
. NETs-associated cytotoxic histones and proteases could injure the 
surrounding endothelium, leading to vascular leakage
59, 69
. 
To study the neutrophil-EC crosstalk, we co-cultured HUVEC with MAC positive 
neutrophils in vitro. MAC positive neutrophils induce gap formation in a confluent EC 
monolayer (Figure 11A). ECIS assay can be used to detect the integrity of EC monolayer, 
and in this study the results show that co-culture with MAC positive neutrophils decreases the 
TEER of an endothelial monolayer, suggesting an increased vascular permeability (Figure 
11B). In vivo, tumor blood vessels with increased levels of neutrophils are characterized by 
IgG leakage from the blood into the adjacent tissue suggesting increased vascular 
permeability (Figure 12A-B).  
To highlight the fundamental role of neutrophils, we blocked neutrophil activation (NETs 
formation) by inhibiting PAD4 in additional in vitro and animal experiments (Figure 11C and 
12C-D).The results indicated that PAD4 inhibitor treatment prevent the neutrophil induced 
break down of the endothelial resistance in vitro and IgG leakage in vivo, suggesting 
neutrophil activation is needed to increase tumor blood vessel permeability. To confirm these 
findings at the functional level, we performed in vivo experiments in C5 deficient mice, 
which are unable to generate the MAC (Figure 13). We found that lack of C5 reduced 
neutrophil recruitment into the tumor tissue underlining the high relevance of C5a for the 
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recruitment neutrophils. In accordance with our conclusion, blood vessel permeability was 
not decreased even in blood vessels with a comparable high amount of neutrophils, indicating 
that neutrophils without MAC are not able to increase the permeability of the tumor blood 
vessel.  
To study the influence of the impaired endothelial barrier on tumor cell extravasation, we 
measured the transmigration of human melanoma cells by transwell assays. As expected, we 
found that the MAC induced increase of the vascular permeability promoted tumor cell 
transmigration (Figure 13E). Moreover, we conducted additional lung metastasis experiments 
in C5 knockout mice (Figure 13F). In agreement with our hypothesis, the inability to generate 
the MAC correlated with a significantly reduced rate of metastasis. We also analyzed human 
skin tumors differing in their metastatic potential to gain further insight into the impact of 
complement activation and the role of MAC formation (Figure 14). In accordance with this 
clinical phenotype and our hypothesis that complement activation contributes to metastasis, 
we detected significantly weaker complement activation and less frequent MAC deposition 
on neutrophils in non-metastatic skin cancers compared to melanoma. This result highlights 
the correlation between complement activation, MAC deposition on neutrophils and cancer 
cell dissemination. It also provides insight into the mechanisms of melanoma metastasis and 
emphasizes the relevance of our findings for the clinical phenotyping of melanoma. 
Taken together, these results demonstrate MAC+ neutrophils play an important role in 
controlling EC paracellular permeability allowing the transmigration and thus metastasis of 
melanoma cells.  
 
4.5 Tinzaparin blocks complement-related neutrophil activation in vitro and in vivo  
Given the pro-tumor effect of the activated complement system, the idea of complement 
inhibition as anti-cancer treatment is gaining recognition
6, 21, 41
. Previous studies identified 
LMWH as potent inhibitor of the complement cascade. Different modes of action have been 
reported including inhibition of C1q binding to immune complexes, blockade of the C3 
convertase formation and inhibition of the MAC assembly
45, 52, 132
. Various complement 
factors and complement regulators react with polysaccharide glycosaminoglycan (GAG) on 
cellular membranes
45
. Accordingly, in our study we observed a positive correlation between 
complement activation (C3b/iC3b deposition) and the glycosylation of the tumor endothelium 
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(WGA staining and syndecan-1 expression, Figure 5B-C). These interactions might serves as 
potential target for blocking complement activation. Heparan sulfate related GAGs especially 
LMWHs can be used to intervene in the interaction of complement factors with 
proteoglycans on the cell membrane or in the extracellular matrix to limit the complement 
activation
45
. In addition, we previously showed that tinzaparin treatment attenuated tumor 
progression and metastatic burden in murine animal models
93, 94
. So, we selected LMWH for 
further complement inhibition studies. 
Tinzaparin is produced by chemical or enzymatic depolymerization of porcine unfractionated 
heparin and it is a heterogeneous carbohydrate mixture with an average molecular weight of 
6.5 kDa
133
. Therefore, tinzaparin is not a single compound, but a mixture of 
glycosaminoglycan chains with different chain lengths and structure features
133, 134
. We first 
checked the complement inhibition effect by tinzaparin in vitro (Figure 15A-B). The CH50 
and APH50 assay were applied to detect the impact of LMWHs on the complement system 
activation. The results show that treatment with tinzaparin significantly blocks the classical 
and alternative pathway activation. Additionally, treatment with the LMWH tinzaparin 
blocked MACs formation on neutrophils (Figure 15C). Taken together, those in vitro 
experiments clearly confirmed the complement inhibitory effects of tinzaparin.  
Because MACs on neutrophils are strong trigger for NETs and ROS production, we next 
analyzed the blocking effect of tinzaparin (Figure 16). DNA-histone fragments are 
significantly reduced or even absent in the supernatants of tinzaparin treated neutrophils. 
Western blot results further prove that tinzaparin could significantly prevent the release of 
CitH3. We next checked the tinzaparin induced complement inhibition efficiency Western 
blot results confirmed that 10 U/ml is the minimal working concentration.  
To measure the complement inhibition efficiency of non-coagulative heparins we analyzed 
commercially available N-acetylheparin (NAH) lacking anti-coagulative properties but still 
owing anti-complement activity
135
. In our analysis we found that NAH was able to efficiently 
block the classical and alternative pathway as measured by CH50 and APH50 assays (Figure 
15A-B). NAH was also able to prevent NETosis. However at equimolar concentrations, NAH 
was significantly less efficient than Tinzaparin, especially the inhibitory effect on NETosis 
(Figure 16A-B). 
In line with the result of NETs detection, treatment with tinzaparin decreases the ROS 
release, which was measured by a chemiluminescence assay (Figure 16C). As MAC positive 
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neutrophils could induce EC dysfunction, we next checked the treatment effect of tinzaparin 
in a neutrophil/HUVEC co-culture system. The TEER result shows that tinzaparin effectively 
abolishes the EC dysfunction through by inhibiting the complement activation effects on 
neutrophils (Figure 16D). 
To further investigate the treatment effect of tinzaparin in vivo, we treated ret tumor engrafted 
mice with tinzaparin, and followed by analysis of complement activation (Figure 17). As 
expected, the C3 fragments deposition along vessel wall in tumor is decreased in tinzaparin 
treated tumor tissue. Furthermore, inhibition of complement activation by tinzaparin blocks 
the MAC deposition on neutrophils.  
LMWHs are used as clinical antithrombotic agents. Indeed, heparin is not a specific blocker 
of the complement but it can also interfere with coagulation and the action of growth factors 
and chemokine
45
. Therefore, clinical usage of heparins to attenuate complement activity 
should be done carefully, and heparins that specifically block complement activation should 
be selected to minimize the cross reactivity with coagulation and non-complement mediated 
inflammation
45
. Within this context we tested the complement and NETs inhibitory activity 
of NAH, a heparin with reduced anti-coagulative properties. However, it was less efficient 
than tinzaparin. Further research is required to optimize potential heparins and heparin related 
molecules to identify subtypes of heparins with precisely defined inhibitory properties.  
 
4.6 Outlook 
Malignant melanoma is an immunogenic tumor. To our knowledge, our manuscript reports 
for the first time the formation of the MAC on tumor-associated neutrophils and considers the 
pathophysiological consequences in melanoma (Figure 18). The complex crosstalk between 
the complement system and immune cells during tumor progression is an emerging field of 
research because many of the pathophysiological mechanisms remain unclear
21, 42
. Notably, 
extensive evidence obtained in experimental models suggests that the complement can 
modulate T cell responses in a variety of inflammatory diseases
21, 42
. However, the impact of 
MAC positive neutrophils on adaptive immune responses in the tumor microenvironment is 
still poorly understood and need further exploration. Recently, Ajona.D et al.
34
 reported the 
blockade of C5a resulted in a substantial improvement in the efficacy of anti PD-1 antibody 
against lung cancer. In this study, we highlight the potential use of LMWH as an anti-
69 
complement reagent. For the treatment of melanoma, a combined blockade of complement 
signaling by tinzaparin with other immunotherapy might be an alternative therapeutic 
strategy. As discussed above, although LMWH can block the complement activation 
efficiently, it is still not a specific inhibitor. So, it would be also worth to investigate the 
subtypes of heparins with precisely defined inhibitory properties. A better understanding of 
heparins and related derivatives will reveal new therapeutic options in the future. Another 
interesting finding is the association between glycosylation and complement activated factor 
deposition in tumor microenvironment. However, the precise biological role of aberrant 
glycosylation on tumor endothelial surface triggering complement activation requires further 
clarification. 
Apart from tumor, complement, neutrophil and EC are also the main participators of many 
immunological, hematological and dermatological related disease. We are convinced that our 
findings and proposed mechanisms (complement factor deposition, neutrophil activation and 
the loss of blood vessel integrity) not only improve the understanding of this triangular 
crosstalk in the context of melanoma progression, but are transferable to other human 
diseases such as vasculitis
136
, thrombotic microangiopathy
131
, immunothrombosis
137
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